These	O
findings	O
should	O
be	O
useful	O
for	O
therapeutic	O
strategies	O
and	O
the	O
development	O
of	O
immunosuppressants	O
targeting	O
the	O
CD28	B-protein
costimulatory	O
pathway	O
.	O


Whereas	O
activation	O
of	O
the	O
HIV-1	B-DNA
enhancer	I-DNA
following	O
T-cell	O
stimulation	O
is	O
mediated	O
largely	O
through	O
binding	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
to	O
two	O
adjacent	O
kappa	B-DNA
B	I-DNA
sites	I-DNA
in	O
the	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
,	O
activation	O
of	O
the	O
HIV-2	B-DNA
enhancer	I-DNA
in	O
monocytes	B-cell_type
and	O
T	B-cell_type
cells	I-cell_type
is	O
dependent	O
on	O
four	O
cis-acting	B-DNA
elements	I-DNA
:	O
a	O
single	O
kappa	B-DNA
B	I-DNA
site	I-DNA
,	O
two	O
purine-rich	B-DNA
binding	I-DNA
sites	I-DNA
,	O
PuB1	B-DNA
and	O
PuB2	B-DNA
,	O
and	O
a	O
pets	B-DNA
site	I-DNA
.	O


We	O
have	O
now	O
identified	O
a	O
novel	O
cis-acting	B-DNA
element	I-DNA
within	O
the	O
HIV-2	B-DNA
enhancer	I-DNA
,	O
immediately	O
upstream	O
of	O
the	O
kappa	B-DNA
B	I-DNA
site	I-DNA
,	O
designated	O
peri-kappa	B-DNA
B	I-DNA
.	O


Understanding	O
the	O
monocyte-specific	O
function	O
of	O
the	O
peri-kappa	B-protein
B	I-protein
factor	I-protein
may	O
ultimately	O
provide	O
insight	O
into	O
the	O
different	O
role	O
monocytes	B-cell_type
and	O
T	B-cell_type
cells	I-cell_type
play	O
in	O
HIV	O
pathogenesis	O
.	O


E1A	B-DNA
gene	I-DNA
expression	O
induces	O
susceptibility	O
to	O
killing	O
by	O
NK	B-cell_type
cells	I-cell_type
following	O
immortalization	O
but	O
not	O
adenovirus	O
infection	O
of	O
human	B-cell_type
cells	I-cell_type
.	O


The	O
inability	O
of	O
E1A	B-DNA
gene	I-DNA
products	O
to	O
induce	O
cytolytic	O
susceptibility	O
during	O
infection	O
was	O
not	O
explained	O
by	O
an	O
inhibitory	O
effect	O
of	O
viral	O
infection	O
on	O
otherwise	O
susceptible	O
target	B-cell_type
cells	I-cell_type
or	O
by	O
viral	B-DNA
gene	I-DNA
effects	O
on	O
class	B-protein
I	I-protein
MHC	I-protein
antigen	I-protein
expression	O
on	O
target	B-cell_type
cells	I-cell_type
.	O


This	O
differential	O
effect	O
of	O
E1A	B-protein
expression	O
on	O
the	O
cytolytic	O
phenotypes	O
of	O
infected	O
and	O
stably	O
transfected	O
human	B-cell_type
cells	I-cell_type
suggests	O
that	O
human	B-cell_type
NK	I-cell_type
cells	I-cell_type
provide	O
an	O
effective	O
immunologic	O
barrier	O
against	O
the	O
in	O
vivo	O
survival	O
and	O
neoplastic	O
progression	O
of	O
E1A-immortalized	B-cell_line
cells	I-cell_line
that	O
may	O
emerge	O
from	O
the	O
reservoir	O
of	O
persistently	B-cell_type
infected	I-cell_type
cells	I-cell_type
in	O
the	O
human	O
host	O
.	O


The	O
CD4	B-protein
coreceptor	I-protein
interacts	O
with	O
non-polymorphic	B-protein
regions	I-protein
of	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
class	I-protein
II	I-protein
molecules	I-protein
on	O
antigen-presenting	B-cell_type
cells	I-cell_type
and	O
contributes	O
to	O
T	O
cell	O
activation	O
.	O


We	O
have	O
investigated	O
the	O
effect	O
of	O
CD4	B-protein
triggering	O
on	O
T	O
cell	O
activating	O
signals	O
in	O
a	O
lymphoma	O
model	O
using	O
monoclonal	B-protein
antibodies	I-protein
(	O
mAb	B-protein
)	O
which	O
recognize	O
different	O
CD4	B-protein
epitopes	I-protein
.	O


Whereas	O
different	O
anti-CD4	B-protein
mAb	I-protein
or	O
HIV-1	B-protein
gp120	I-protein
could	O
all	O
trigger	O
activation	O
of	O
the	O
protein	B-protein
tyrosine	I-protein
kinases	I-protein
p56lck	B-protein
and	O
p59fyn	B-protein
and	O
phosphorylation	O
of	O
the	O
Shc	B-protein
adaptor	I-protein
protein	I-protein
,	O
which	O
mediates	O
signals	O
to	O
Ras	B-protein
,	O
they	O
differed	O
significantly	O
in	O
their	O
ability	O
to	O
activate	O
NF-AT	B-protein
.	O


The	O
results	O
identify	O
functionally	O
distinct	O
epitopes	B-protein
on	O
the	O
CD4	B-protein
coreceptor	I-protein
involved	O
in	O
activation	O
of	O
the	O
Ras/protein	B-protein
kinase	I-protein
C	I-protein
and	O
calcium	O
pathways	O
.	O


In	O
chickens	O
,	O
estrogens	O
stimulate	O
outgrowth	O
of	O
bone	B-cell_type
marrow-derived	I-cell_type
erythroid	I-cell_type
progenitor	I-cell_type
cells	I-cell_type
and	O
delay	O
their	O
maturation	O
.	O


We	O
demonstrate	O
that	O
the	O
transcriptional	O
activity	O
of	O
GATA-1	B-protein
is	O
strongly	O
repressed	O
by	O
the	O
estrogen	B-protein
receptor	I-protein
(	O
ER	B-protein
)	O
in	O
a	O
ligand-dependent	O
manner	O
and	O
that	O
this	O
repression	O
is	O
reversible	O
in	O
the	O
presence	O
of	O
4-hydroxytamoxifen	O
.	O


In	O
coimmunoprecipitation	O
experiments	O
using	O
transfected	O
COS	B-cell_line
cells	I-cell_line
,	O
GATA-1	B-protein
and	O
ER	B-protein
associate	O
in	O
a	O
ligand-dependent	O
manner	O
.	O


We	O
speculate	O
that	O
estrogens	O
exert	O
effects	O
on	O
erythropoiesis	O
by	O
modulating	O
GATA-1	B-protein
activity	O
through	O
protein-protein	O
interaction	O
with	O
the	O
ER	B-protein
.	O


Mouse	B-DNA
interleukin-2	I-DNA
receptor	I-DNA
alpha	I-DNA
gene	I-DNA
expression	O
.	O


Interleukin-1	B-protein
and	O
interleukin-2	B-protein
control	O
transcription	O
via	O
distinct	O
cis-acting	B-DNA
elements	I-DNA
.	O


Here	O
we	O
map	O
the	O
cis-acting	B-DNA
elements	I-DNA
that	O
mediate	O
interleukin	O
responsiveness	O
of	O
the	O
mouse	B-DNA
IL-2R	I-DNA
alpha	I-DNA
gene	I-DNA
using	O
a	O
thymic	B-cell_line
lymphoma-derived	I-cell_line
hybridoma	I-cell_line
(	O
PC60	B-cell_line
)	O
.	O


IL-1	B-protein
induces	O
a	O
rapid	O
,	O
protein	O
synthesis-independent	O
appearance	O
of	O
IL-2R	B-RNA
alpha	I-RNA
mRNA	I-RNA
that	O
is	O
blocked	O
by	O
inhibitors	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O


Transient	O
transfection	O
experiments	O
show	O
that	O
several	O
elements	O
in	O
the	O
promoter-proximal	B-DNA
region	I-DNA
of	O
the	O
IL-2R	B-DNA
alpha	I-DNA
gene	I-DNA
contribute	O
to	O
IL-1	B-protein
responsiveness	O
,	O
most	O
importantly	O
an	O
NF-kappa	B-DNA
B	I-DNA
site	I-DNA
conserved	O
in	O
the	O
human	B-DNA
and	I-DNA
mouse	I-DNA
gene	I-DNA
.	O


This	O
segment	O
functions	O
as	O
an	O
IL-2-inducible	B-DNA
enhancer	I-DNA
and	O
lies	O
within	O
a	O
region	O
that	O
becomes	O
DNase	B-protein
I	I-protein
hypersensitive	O
in	O
normal	O
T	B-cell_type
cells	I-cell_type
in	O
which	O
IL-2R	B-protein
alpha	I-protein
expression	O
has	O
been	O
induced	O
.	O


This	O
review	O
focuses	O
on	O
the	O
roles	O
of	O
transcription	B-protein
factors	I-protein
in	O
hematopoietic	O
lineage	O
commitment	O
.	O


A	O
brief	O
introduction	O
to	O
lineage	O
commitment	O
and	O
asymmetric	O
cell	O
division	O
is	O
followed	O
by	O
a	O
discussion	O
of	O
several	O
methods	O
used	O
to	O
identify	O
transcription	B-protein
factors	I-protein
important	O
in	O
specifying	O
hematopoietic	B-cell_type
cell	I-cell_type
types	I-cell_type
.	O


Next	O
is	O
presented	O
a	O
discussion	O
of	O
the	O
use	O
of	O
embryonic	B-cell_type
stem	I-cell_type
cells	I-cell_type
in	O
the	O
analysis	O
of	O
hematopoietic	B-DNA
gene	I-DNA
expression	O
and	O
the	O
use	O
of	O
targeted	O
gene	O
disruption	O
to	O
analyze	O
the	O
role	O
of	O
transcription	B-protein
factors	I-protein
in	O
hematopoiesis	O
.	O


We	O
and	O
others	O
have	O
shown	O
that	O
EBV	O
can	O
also	O
infect	O
a	O
subset	O
of	O
thymocytes	B-cell_type
.	O


ZEBRA	B-protein
protein	I-protein
was	O
also	O
identified	O
in	O
infected	O
thymocytes	B-cell_type
by	O
immunoprecipitation	O
.	O


In	O
addition	O
,	O
we	O
demonstrated	O
that	O
the	O
EBNA-1	B-DNA
gene	I-DNA
in	O
infected	O
thymocytes	B-cell_type
was	O
transcribed	O
from	O
the	O
Fp	B-DNA
promoter	I-DNA
,	O
rather	O
than	O
from	O
the	O
Cp/Wp	B-DNA
promoter	I-DNA
which	O
is	O
used	O
in	O
latently	B-cell_type
infected	I-cell_type
B	I-cell_type
cells	I-cell_type
.	O


Transcripts	O
encoding	O
gp350/220	B-protein
,	O
the	O
major	B-protein
coat	I-protein
protein	I-protein
of	O
EBV	O
,	O
were	O
identified	O
,	O
but	O
we	O
did	O
not	O
find	O
any	O
evidence	O
of	O
transcription	O
from	O
the	O
LMP-2A	B-DNA
or	O
EBER-1	B-DNA
loci	I-DNA
in	O
infected	O
thymocytes	B-cell_type
.	O


These	O
observations	O
suggest	O
that	O
de	O
novo	O
EBV	O
infection	O
of	O
thymocytes	B-cell_type
differs	O
from	O
infection	O
of	O
B	B-cell_type
cells	I-cell_type
.	O


Rather	O
,	O
EBV	O
remains	O
in	O
a	O
linear	O
configuration	O
from	O
which	O
replicative	B-DNA
genes	I-DNA
are	O
transcribed	O
.	O


Identification	O
and	O
purification	O
of	O
human	B-protein
Stat	I-protein
proteins	I-protein
activated	O
in	O
response	O
to	O
interleukin-2	B-protein
.	O


Several	O
recent	O
studies	O
have	O
implicated	O
Jak	O
kinases	O
in	O
the	O
signaling	O
pathway	O
induced	O
by	O
IL-2	B-protein
.	O


We	O
have	O
purified	O
these	O
activities	O
and	O
found	O
that	O
the	O
principal	O
IL-2-inducible	B-protein
component	I-protein
bears	O
significant	O
relatedness	O
to	O
a	O
prolactin-induced	B-protein
transcription	I-protein
factor	I-protein
first	O
identified	O
in	O
sheep	B-cell_type
mammary	I-cell_type
gland	I-cell_type
tissue	I-cell_type
.	O


We	O
hypothesize	O
that	O
activation	O
of	O
this	O
protein	O
,	O
designated	O
hStat5	B-protein
,	O
helps	O
govern	O
the	O
biological	O
effects	O
of	O
IL-2	B-protein
during	O
the	O
immune	O
response	O
.	O


We	O
demonstrate	O
,	O
through	O
the	O
deletion	O
of	O
the	O
human	B-DNA
UDG	I-DNA
promoter	I-DNA
sequences	I-DNA
,	O
that	O
expression	O
of	O
E2F-1	B-protein
activates	O
the	O
UDG	B-DNA
promoter	I-DNA
through	O
several	O
E2F	B-DNA
sites	I-DNA
.	O


We	O
also	O
provide	O
evidence	O
for	O
the	O
functional	O
relationship	O
between	O
the	O
cyclin-like	B-protein
UDG	I-protein
gene	I-protein
product	I-protein
and	O
E2F	B-protein
.	O


High	O
levels	O
of	O
UDG	B-protein
expression	O
in	O
a	O
transient	O
transfection	O
assay	O
result	O
in	O
the	O
down-regulation	O
of	O
transcriptional	O
activity	O
through	O
elements	B-DNA
specific	O
for	O
E2F	B-protein
-mediated	O
transcription	O
.	O


Cellular	O
and	O
molecular	O
mechanisms	O
of	O
IFN-gamma	B-protein
production	O
induced	O
by	O
IL-2	B-protein
and	O
IL-12	B-protein
in	O
a	O
human	B-cell_line
NK	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O


In	O
particular	O
,	O
two	O
interleukins	B-protein
(	O
ILs	B-protein
)	O
,	O
IL-2	B-protein
and	O
IL-12	B-protein
,	O
have	O
been	O
shown	O
to	O
be	O
potent	O
inducers	O
of	O
IFN-gamma	B-protein
gene	O
expression	O
in	O
both	O
T	B-cell_type
cells	I-cell_type
and	O
LGL	B-cell_type
.	O


In	O
this	O
report	O
we	O
present	O
evidence	O
that	O
the	O
cell	B-cell_line
line	I-cell_line
NK3.3	I-cell_line
derived	O
from	O
human	B-cell_type
NK	I-cell_type
cells	I-cell_type
,	O
responds	O
to	O
both	O
IL-2	B-protein
and	O
IL-12	B-protein
,	O
as	O
measured	O
by	O
increases	O
in	O
IFN-gamma	B-protein
and	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
cytoplasmic	O
mRNA	O
and	O
protein	O
expression	O
.	O


In	O
addition	O
,	O
when	O
used	O
together	O
IL-2	B-protein
and	O
IL-12	B-protein
synergized	O
in	O
the	O
induction	O
of	O
IFN-gamma	B-protein
and	O
GM-CSF	B-protein
and	O
this	O
synergy	O
was	O
attributed	O
to	O
an	O
increased	O
accumulation	O
and	O
stability	O
of	O
the	O
IFN-gamma	B-RNA
and	I-RNA
GM-CSF	I-RNA
mRNAs	I-RNA
.	O


Furthermore	O
,	O
both	O
transforming	B-protein
growth	I-protein
factor-beta	I-protein
and	O
genistein	O
,	O
a	O
tyrosine	O
kinase	O
inhibitor	O
,	O
could	O
suppress	O
IL-2	B-protein
and	O
IL-12	B-protein
signaling	O
but	O
CsA	O
was	O
generally	O
inactive	O
.	O


These	O
data	O
indicate	O
that	O
IL-2	B-protein
and	O
IL-12	B-protein
may	O
have	O
distinct	O
signaling	O
pathways	O
leading	O
to	O
the	O
induction	O
of	O
IFN-gamma	B-protein
and	O
GM-CSF	B-protein
gene	O
expression	O
,	O
and	O
that	O
the	O
NK3.3	B-cell_line
cell	I-cell_line
line	I-cell_line
may	O
serve	O
as	O
a	O
novel	O
model	O
for	O
dissecting	O
the	O
biochemical	O
and	O
molecular	O
events	O
involved	O
in	O
these	O
pathways	O
.	O


A	O
functional	O
T-cell	B-protein
receptor	I-protein
signaling	O
pathway	O
is	O
required	O
for	O
p95vav	B-protein
activity	O
.	O


It	O
contains	O
a	O
number	O
of	O
structural	B-protein
motifs	I-protein
,	O
including	O
Src	B-protein
homology	I-protein
2	I-protein
,	I-protein
Src	I-protein
homology	I-protein
3	I-protein
,	I-protein
and	I-protein
pleckstrin	I-protein
homology	I-protein
domains	I-protein
and	O
a	O
putative	B-protein
guanine	I-protein
nucleotide	I-protein
exchange	I-protein
domain	I-protein
.	O


Furthermore	O
,	O
p95vav	B-protein
synergizes	O
with	O
TCR	B-protein
stimulation	O
in	O
inducing	O
NFAT-	O
and	O
interleukin-2-dependent	O
transcription	O
.	O


We	O
further	O
demonstrate	O
that	O
the	O
p95vav	B-protein
-induced	O
NFAT	B-protein
activation	O
is	O
not	O
mimicked	O
by	O
Ras	B-protein
activation	O
,	O
though	O
its	O
function	O
is	O
dependent	O
upon	O
Ras	B-protein
and	O
Raf	B-protein
.	O


However	O
,	O
overexpression	O
of	O
p95vav	B-protein
does	O
not	O
appear	O
to	O
influence	O
TCR	B-protein
-induced	O
protein	O
tyrosine	O
phosphorylation	O
or	O
increases	O
in	O
cytoplasmic	O
free	O
calcium	O
.	O


Positive	O
and	O
negative	O
regulation	O
of	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
promoter	O
activity	O
by	O
AML1-related	B-protein
transcription	I-protein
factor	I-protein
,	O
PEBP2	B-protein
.	O


There	O
are	O
at	O
least	O
two	O
genes	O
,	O
alpha	B-DNA
A	I-DNA
and	O
alpha	B-DNA
B	I-DNA
,	O
encoding	O
the	O
alpha	B-protein
subunit	I-protein
.	O


alpha	B-DNA
B	I-DNA
is	O
the	O
mouse	B-DNA
homologue	I-DNA
of	O
human	B-DNA
AML1	I-DNA
gene	I-DNA
detected	O
at	O
the	O
breakpoints	O
of	O
t	O
(	O
8	O
;	O
21	O
)	O
and	O
t	O
(	O
3	O
;	O
21	O
)	O
myeloid	O
leukemias	O
.	O


PEBP2	B-protein
alpha	I-protein
A1	I-protein
and	O
alpha	B-protein
B1	I-protein
enhanced	O
the	O
expression	O
of	O
the	O
GM-CSF	B-DNA
promoter-driven	I-DNA
reporter	I-DNA
plasmid	I-DNA
in	O
unstimulated	B-cell_line
and	I-cell_line
12-O-tetradecanoylphorbol	I-cell_line
13-acetate/phytohemagglutinin-stimulated	I-cell_line
human	I-cell_line
Jurkat	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O


Coexpression	O
of	O
alpha	B-protein
B1	I-protein
and	O
alpha	B-protein
B2	I-protein
showed	O
that	O
the	O
promoter	O
activity	O
could	O
be	O
determined	O
by	O
the	O
alpha	B-protein
B1	I-protein
/alpha	B-protein
B2	I-protein
ratio	O
.	O


Although	O
further	O
studies	O
are	O
required	O
to	O
determine	O
the	O
precise	O
role	O
of	O
PEBP2	B-protein
in	O
the	O
GM-CSF	B-protein
promoter	O
activity	O
,	O
the	O
present	O
findings	O
suggested	O
the	O
importance	O
of	O
the	O
relative	O
ratio	O
of	O
different	O
PEBP2	B-protein
isoforms	I-protein
in	O
regulating	O
the	O
levels	O
of	O
the	O
promoter	O
activity	O
.	O


IFN-gamma	B-protein
priming	O
of	O
monocytes	B-cell_type
enhances	O
LPS-induced	O
TNF	B-protein
production	O
by	O
augmenting	O
both	O
transcription	O
and	O
MRNA	O
stability	O
.	O


Using	O
tumour	B-protein
necrosis	I-protein
factor	I-protein
(	O
TNF	B-protein
)	O
induction	O
as	O
a	O
model	O
,	O
experiments	O
were	O
designed	O
to	O
analyse	O
in	O
detail	O
the	O
priming	O
effect	O
on	O
the	O
LPS	O
response	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O


IFN-gamma	B-protein
pre-treatment	O
affected	O
the	O
magnitude	O
rather	O
than	O
the	O
sensitivity	O
of	O
the	O
LPS	O
response	O
.	O


The	O
increased	O
transcriptional	O
rate	O
correlated	O
with	O
a	O
marked	O
increase	O
in	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
activity	O
in	O
these	O
cells	O
as	O
determined	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
using	O
a	O
consensus	B-DNA
NF-kappa	I-DNA
B	I-DNA
oligonucleotide	I-DNA
.	O


Consistent	O
with	O
the	O
increased	O
mRNA	B-RNA
stability	O
,	O
the	O
duration	O
of	O
mRNA	B-RNA
accumulation	O
was	O
longer	O
following	O
LPS	O
stimulation	O
in	O
primed	O
monocytes	B-cell_type
,	O
in	O
addition	O
to	O
being	O
of	O
greater	O
magnitude	O
.	O


Using	O
biochemical	O
and	O
mutagenesis	O
analyses	O
,	O
we	O
determined	O
that	O
multiple	O
nuclear	B-protein
factors	I-protein
bind	O
to	O
these	O
independent	O
sites	O
.	O


We	O
determined	O
that	O
an	O
initiator-like	B-DNA
sequence	I-DNA
present	O
at	O
the	O
cap	B-DNA
site	I-DNA
and	O
an	O
Ets	B-DNA
consensus	I-DNA
sequence	I-DNA
are	O
required	O
for	O
full	O
promoter	B-DNA
function	O
.	O


We	O
therefore	O
believe	O
that	O
the	O
MAZ	B-protein
transcription	I-protein
factor	I-protein
is	O
also	O
likely	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
control	O
of	O
developmental	O
expression	O
of	O
the	O
CD4	B-DNA
gene	I-DNA
.	O


The	O
protein	B-protein
products	I-protein
of	O
this	O
gene	O
contain	O
the	O
basic-helix-loop-helix	B-protein
motif	I-protein
characteristic	O
of	O
a	O
large	O
family	O
of	O
transcription	B-protein
factors	I-protein
that	O
bind	O
to	O
the	O
canonical	B-DNA
DNA	I-DNA
sequence	I-DNA
CANNTG	I-DNA
as	O
protein	B-protein
heterodimers	I-protein
.	O


These	O
results	O
indicate	O
that	O
Epo	B-protein
acts	O
at	O
both	O
transcriptional	O
and	O
posttranscriptional	O
levels	O
on	O
the	O
TAL1	B-protein
locus	O
in	O
Friend	B-cell_line
virus-induced	I-cell_line
erythroblasts	I-cell_line
and	O
establish	O
a	O
link	O
between	O
Epo	B-protein
signaling	O
mechanisms	O
and	O
a	O
member	O
of	O
a	O
family	O
of	O
transcription	B-protein
factors	I-protein
involved	O
in	O
the	O
differentiation	O
of	O
diverse	B-cell_type
cell	I-cell_type
lineages	I-cell_type
.	O


This	O
technique	O
was	O
successfully	O
applied	O
to	O
evaluate	O
differences	O
in	O
glucocorticoid	B-protein
receptor	I-protein
expression	O
in	O
U937	B-cell_line
cells	I-cell_line
before	O
and	O
after	O
the	O
addition	O
of	O
potent	O
differentiation	O
inducers	O
:	O
12-O-tetradecanoylphorbol	O
13-acetate	O
(	O
TPA	O
)	O
and	O
a	O
combination	O
of	O
all-trans	O
retinoic	O
acid	O
(	O
RA	O
)	O
and	O
1	O
,	O
25-dihydroxyvitamin	O
D2	O
(	O
VD	O
)	O
.	O


In	O
contrast	O
to	O
the	O
purely	O
enhancer-dependent	O
effect	O
of	O
cytokines	B-protein
such	O
as	O
TNF	B-protein
on	O
the	O
activity	O
of	O
the	O
HIV	B-DNA
regulatory	I-DNA
region	I-DNA
(	O
LTR	B-DNA
)	O
,	O
we	O
observed	O
that	O
okadaic	O
acid	O
(	O
OKA	O
)	O
activates	O
HIV	O
transcription	O
through	O
both	O
the	O
enhancer	O
,	O
responding	O
to	O
the	O
factor	O
NF-kappa	B-protein
B	I-protein
,	O
and	O
the	O
promoter	B-DNA
domain	I-DNA
of	O
the	O
LTR	B-DNA
.	O


Responsiveness	O
of	O
LTR	B-DNA
constructs	I-DNA
deleted	O
of	O
kappa	B-DNA
B	I-DNA
elements	I-DNA
to	O
HIV	B-protein
Tat	I-protein
expression	O
was	O
increased	O
upon	O
OKA	O
but	O
not	O
TNF	B-protein
stimulation	O
.	O


Our	O
results	O
suggest	O
that	O
SP1	B-protein
phosphorylation	O
induced	O
by	O
OKA	O
,	O
a	O
selective	O
inhibitor	O
of	O
the	O
serine-threonine	B-protein
phosphatase	I-protein
PP2A	B-protein
,	O
facilitates	O
the	O
formation	O
of	O
a	O
transcription	B-protein
complex	I-protein
involving	O
general	O
transcription	B-protein
factors	I-protein
,	O
HIV	B-protein
Tat	I-protein
,	O
and	O
Sp1	B-protein
proteins	I-protein
.	O


To	O
understand	O
the	O
molecular	O
bases	O
for	O
cytokine	O
redundancy	O
and	O
pleiotropy	O
,	O
we	O
have	O
compared	O
the	O
Stat	B-protein
proteins	I-protein
activated	O
in	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
(	O
PBLs	B-cell_type
)	O
by	O
cytokines	B-protein
with	O
shared	O
and	O
distinct	O
actions	O
.	O


IL-7	B-protein
and	O
IL-15	B-protein
induced	O
the	O
same	O
complexes	O
as	O
IL-2	B-protein
,	O
a	O
feature	O
explained	O
by	O
the	O
existence	O
of	O
similar	O
tyrosine-phosphorylated	B-protein
motifs	I-protein
in	O
the	O
cytoplasmic	B-protein
domains	I-protein
of	O
IL-2R	B-protein
beta	I-protein
and	O
IL-7R	B-protein
that	O
can	O
serve	O
as	O
docking	O
sites	O
for	O
Stat	B-protein
proteins	I-protein
.	O


These	O
studies	O
demonstrate	O
that	O
a	O
single	O
cytokine	B-protein
can	O
activate	O
different	O
combinations	O
of	O
Stat	B-protein
proteins	I-protein
under	O
different	O
physiological	O
conditions	O
,	O
and	O
also	O
indicate	O
two	O
mechanisms	O
by	O
which	O
distinct	O
cytokines	B-protein
can	O
activate	O
the	O
same	O
Stat	B-protein
protein	I-protein
.	O


Various	O
stimuli	O
,	O
typically	O
those	O
associated	O
with	O
stress	O
or	O
pathogens	O
,	O
rapidly	O
inactivate	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
.	O


When	O
either	O
serine-32	O
or	O
serine-36	O
of	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
was	O
mutated	O
,	O
the	O
protein	O
did	O
not	O
undergo	O
signal-induced	O
phosphorylation	O
or	O
degradation	O
,	O
and	O
NF-kappa	B-protein
B	I-protein
could	O
not	O
be	O
activated	O
.	O


Regulation	O
of	O
transcription	O
of	O
the	O
human	B-DNA
erythropoietin	I-DNA
receptor	I-DNA
gene	I-DNA
by	O
proteins	O
binding	O
to	O
GATA-1	B-DNA
and	I-DNA
Sp1	I-DNA
motifs	I-DNA
.	O


Erythropoietin	B-protein
(	O
Epo	B-protein
)	O
,	O
the	O
primary	O
regulator	O
of	O
the	O
production	O
of	O
erythroid	B-cell_type
cells	I-cell_type
,	O
acts	O
by	O
binding	O
to	O
a	O
cell	B-protein
surface	I-protein
receptor	I-protein
(	O
EpoR	B-protein
)	O
on	O
erythroid	B-cell_type
progenitors	I-cell_type
.	O


The	O
150	B-DNA
bp	I-DNA
hEpoR	I-DNA
promoter	I-DNA
exhibited	O
high	O
and	O
low	O
activity	O
in	O
erythroid	O
OCIM1	B-cell_line
and	O
K562	B-cell_line
cells	I-cell_line
,	O
respectively	O
,	O
reflecting	O
the	O
high	O
and	O
low	O
levels	O
of	O
constitutive	O
hEpoR	B-protein
expression	O
.	O


The	O
GATA-1	B-DNA
and	I-DNA
Sp1	I-DNA
binding	I-DNA
sites	I-DNA
in	O
this	O
promoter	O
lacking	O
a	O
TATA	B-DNA
sequence	I-DNA
were	O
necessary	O
for	O
a	O
high	O
level	O
of	O
transcription	O
activation	O
.	O


By	O
increasing	O
GATA-1	B-protein
levels	O
via	O
co-transfection	O
,	O
we	O
were	O
able	O
to	O
transactivate	O
the	O
hEpoR	B-DNA
promoter	I-DNA
in	O
K562	B-cell_line
cells	I-cell_line
and	O
non-erythroid	B-cell_type
cells	I-cell_type
,	O
but	O
not	O
in	O
the	O
highly	O
active	O
OCIM1	B-cell_type
cells	I-cell_type
,	O
although	O
GATA-1	B-RNA
mRNA	I-RNA
levels	O
were	O
comparable	O
in	O
OCIM1	B-cell_line
and	O
K562	B-cell_line
.	O


These	O
data	O
suggest	O
that	O
while	O
GATA-1	B-protein
can	O
transactivate	O
the	O
EpoR	B-DNA
promoter	I-DNA
,	O
the	O
level	O
of	O
hEpoR	B-DNA
gene	I-DNA
expression	O
does	O
not	O
depend	O
on	O
GATA-1	B-protein
alone	O
.	O


The	O
deduced	O
amino	O
acid	O
sequence	O
similarity	O
to	O
the	O
proteins	O
encoded	O
by	O
these	O
two	O
latter	O
genes	O
is	O
approximately	O
65	O
%	O
and	O
includes	O
domains	O
and	O
amino	O
acid	O
residues	O
(	O
the	O
leucine	B-protein
zipper-like	I-protein
and	O
the	O
RGD	B-protein
domain	I-protein
,	O
a	O
serine	O
and	O
a	O
histidine	O
residue	O
in	O
the	O
NH2-	B-protein
and	O
in	O
the	O
COOH-terminal	B-protein
portion	I-protein
of	O
the	O
protein	O
,	O
respectively	O
)	O
postulated	O
to	O
be	O
important	O
for	O
nm23	B-protein
function	O
.	O


An	O
interferon-gamma	B-DNA
activation	I-DNA
sequence	I-DNA
mediates	O
the	O
transcriptional	O
regulation	O
of	O
the	O
IgG	B-DNA
Fc	I-DNA
receptor	I-DNA
type	I-DNA
IC	I-DNA
gene	I-DNA
by	O
interferon-gamma	B-protein
.	O


We	O
observed	O
that	O
Fc	B-protein
gamma	I-protein
RI	I-protein
transcript	O
levels	O
in	O
monoblast-like	B-cell_line
U937	I-cell_line
cells	I-cell_line
were	O
elevated	O
within	O
3	O
hr	O
and	O
peaked	O
12	O
hr	O
after	O
exposure	O
to	O
IFN-gamma	B-protein
.	O


Double-stranded	B-DNA
GIRE	I-DNA
sequence	I-DNA
,	O
but	O
not	O
a	O
scrambled	B-DNA
sequence	I-DNA
,	O
was	O
specifically	O
bound	O
by	O
nuclear	B-protein
proteins	I-protein
from	O
IFN-gamma	B-cell_line
treated	I-cell_line
U937	I-cell_line
cells	I-cell_line
.	O


The	O
Fc	B-DNA
gamma	I-DNA
RIC	I-DNA
GIRE	I-DNA
is	O
homologous	O
to	O
the	O
IFN-gamma	B-DNA
activation	I-DNA
sequence	I-DNA
(	O
GAS	B-DNA
)	O
of	O
the	O
guanylate	B-protein
binding	I-protein
protein	I-protein
and	O
to	O
X	B-DNA
box	I-DNA
elements	I-DNA
of	O
class	B-DNA
II	I-DNA
MHC	I-DNA
genes	I-DNA
.	O


Constitutively	O
activated	O
Jak	B-protein
-STAT	B-protein
pathway	O
in	O
T	B-cell_type
cells	I-cell_type
transformed	O
with	O
HTLV-I	O
.	O


Whereas	O
the	O
Jak	B-protein
kinases	I-protein
Jak1	B-protein
and	O
Jak3	B-protein
and	O
the	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	B-protein
proteins	I-protein
Stat3	B-protein
and	O
Stat5	B-protein
are	O
activated	O
in	O
normal	B-cell_type
T	I-cell_type
cells	I-cell_type
in	O
response	O
to	O
IL-2	B-protein
,	O
this	O
signaling	O
pathway	O
was	O
constitutively	O
activated	O
in	O
HTLV-I-transformed	B-cell_line
cells	I-cell_line
.	O


In	O
HTLV-I-infected	B-cell_line
cord	I-cell_line
blood	I-cell_line
lymphocytes	I-cell_line
,	O
the	O
transition	O
from	O
IL-2	B-protein
-dependent	O
to	O
IL-2	B-protein
-independent	O
growth	O
correlated	O
with	O
the	O
acquisition	O
of	O
a	O
constitutively	O
activated	O
Jak	B-protein
-STAT	B-protein
pathway	O
,	O
which	O
suggests	O
that	O
this	O
pathway	O
participates	O
in	O
HTLV-I-mediated	O
T	O
cell	O
transformation	O
.	O


Nitric	O
oxide	O
decreases	O
cytokine	B-protein
-induced	O
endothelial	O
activation	O
.	O


In	O
a	O
concentration-dependent	O
manner	O
,	O
NO	O
inhibited	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-1	I-protein
alpha-stimulated	O
VCAM-1	B-protein
expression	O
by	O
35-55	O
%	O
as	O
determined	O
by	O
cell	O
surface	O
enzyme	O
immunoassays	O
and	O
flow	O
cytometry	O
.	O


NO	O
also	O
decreased	O
the	O
endothelial	O
expression	O
of	O
other	O
leukocyte	B-protein
adhesion	I-protein
molecules	I-protein
(	O
E-selectin	B-protein
and	O
to	O
a	O
lesser	O
extent	O
,	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
)	O
and	O
secretable	O
cytokines	B-protein
(	O
IL-6	B-protein
and	O
IL-8	B-protein
)	O
.	O


Nuclear	O
run-on	O
assays	O
,	O
transfection	O
studies	O
using	O
various	O
VCAM-1	B-DNA
promoter	I-DNA
reporter	I-DNA
gene	I-DNA
constructs	I-DNA
,	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
indicated	O
that	O
NO	O
represses	O
VCAM-1	B-protein
gene	O
transcription	O
,	O
in	O
part	O
,	O
by	O
inhibiting	O
NF-kappa	B-protein
B	I-protein
.	O


Secreted	O
from	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
macrophages	B-cell_type
,	O
bone	O
marrow-derived	B-protein
MIP-1	I-protein
alpha/GOS19	I-protein
inhibits	O
primitive	B-cell_type
hematopoietic	I-cell_type
stem	I-cell_type
cells	I-cell_type
and	O
appears	O
to	O
be	O
involved	O
in	O
the	O
homeostatic	O
control	O
of	O
stem	B-cell_type
cell	I-cell_type
proliferation	O
.	O


It	O
also	O
induces	O
chemotaxis	O
and	O
inflammatory	O
responses	O
in	O
mature	B-cell_type
cell	I-cell_type
types	I-cell_type
.	O


Therefore	O
,	O
it	O
is	O
important	O
to	O
understand	O
the	O
mechanisms	O
which	O
control	O
the	O
expression	O
of	O
MIP-1	B-protein
alpha	I-protein
/GOS19	B-protein
.	O


Previous	O
work	O
has	O
shown	O
that	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
,	O
a	O
set	O
of	O
widely	O
expressed	O
transcription	B-protein
factors	I-protein
(	O
the	O
ICK-1	B-protein
family	I-protein
)	O
affect	O
the	O
GOS19	B-DNA
promoter	I-DNA
.	O


In	O
this	O
communication	O
,	O
we	O
provide	O
evidence	O
that	O
the	O
pathway	O
of	O
induction	O
in	O
the	O
macrophage	B-cell_line
cell	I-cell_line
line	I-cell_line
U937	B-cell_line
is	O
different	O
from	O
that	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
.	O


A	O
mutation	O
of	O
the	O
MNP	B-DNA
site	I-DNA
which	O
does	O
not	O
abrogate	O
ICK-1	O
binding	O
inactivates	O
the	O
GOS19.1	B-DNA
promoter	I-DNA
in	O
U937	B-cell_line
cells	I-cell_line
and	O
reduces	O
its	O
activity	O
by	O
fourfold	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
.	O


We	O
propose	O
that	O
the	O
MNP	B-protein
protein	I-protein
(	O
s	O
)	O
binding	O
at	O
the	O
MNP	B-DNA
site	I-DNA
constitutes	O
a	O
novel	O
transcription	B-protein
factor	I-protein
(	O
s	O
)	O
expressed	O
in	O
hematopoietic	B-cell_type
cells	I-cell_type
.	O


Toremifene	O
exerts	O
multiple	O
and	O
varied	O
effects	O
on	O
the	O
gene	O
expression	O
of	O
human	B-cell_type
peripheral	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O


IL-5	B-protein
also	O
stimulates	O
GTP	O
binding	O
to	O
p21ras	B-protein
.	O


Jak2	B-protein
kinase	I-protein
has	O
been	O
shown	O
to	O
phosphorylate	O
STAT	B-protein
nuclear	I-protein
proteins	I-protein
.	O


We	O
found	O
that	O
IL-5	B-protein
induces	O
two	O
GAS-binding	B-protein
proteins	I-protein
in	O
eosinophils	B-cell_type
,	O
one	O
of	O
which	O
is	O
STAT1	B-protein
.	O


It	O
is	O
a	O
potent	O
transcriptional	B-protein
activator	I-protein
of	O
many	O
viral	B-DNA
and	I-DNA
cellular	I-DNA
promoters	I-DNA
.	O


However	O
,	O
unlike	O
another	O
tumor	B-protein
suppressor	I-protein
protein	I-protein
,	O
p53	B-protein
,	O
Rb	B-protein
did	O
not	O
have	O
any	O
significant	O
effect	O
on	O
basal	O
levels	O
of	O
transcription	O
,	O
suggesting	O
that	O
Rb	B-protein
specifically	O
interacts	O
with	O
IE2	B-protein
rather	O
than	O
other	O
cellular	B-protein
factors	I-protein
involved	O
in	O
the	O
general	O
transcription	O
machinery	O
.	O


Our	O
results	O
suggest	O
that	O
Rb	B-protein
may	O
regulate	O
the	O
life	O
cycle	O
of	O
HCMV	O
,	O
which	O
is	O
endemic	O
in	O
the	O
human	O
population	O
.	O


In	O
order	O
to	O
determine	O
whether	O
NDP	B-protein
kinase	I-protein
expression	O
serves	O
as	O
a	O
marker	O
for	O
metastatic	O
potential	O
in	O
human	O
skin	O
cancer	O
,	O
we	O
assessed	O
the	O
levels	O
of	O
NDP	B-protein
kinase	I-protein
expression	O
in	O
9	O
keratoacanthomas	O
(	O
KAs	O
)	O
,	O
26	O
squamous	O
cell	O
carcinomas	O
(	O
SCCs	O
)	O
,	O
and	O
25	O
basal	O
cell	O
carcinomas	O
(	O
BCCs	O
)	O
using	O
immunohistochemistry	O
.	O


And	O
there	O
was	O
no	O
statistically	O
significant	O
difference	O
in	O
NDP	B-protein
kinase	I-protein
expression	O
between	O
SCC	O
with	O
metastasis	O
and	O
SCC	O
without	O
metastasis	O
.	O


Our	O
results	O
contradict	O
the	O
hypothesis	O
concerning	O
the	O
possible	O
role	O
of	O
nm23	B-DNA
gene	I-DNA
as	O
a	O
metastatic	O
suppressor	O
gene	O
in	O
human	O
skin	O
cancer	O
.	O


The	O
major	B-DNA
histocompatibility	I-DNA
(	I-DNA
MHC	I-DNA
)	I-DNA
class	I-DNA
II	I-DNA
genes	I-DNA
encode	O
cell	B-protein
surface	I-protein
proteins	I-protein
that	O
bind	O
antigenic	O
peptide	O
for	O
presentation	O
to	O
T-cells	B-cell_type
.	O


RB-defective	B-cell_line
tumor	I-cell_line
lines	I-cell_line
are	O
non-inducible	O
for	O
MHC	B-protein
class	I-protein
II	I-protein
by	O
IFN-gamma	B-protein
,	O
or	O
very	O
weakly	O
inducible	O
,	O
but	O
transfection	O
of	O
2	O
different	O
lines	O
with	O
RB	B-DNA
expression	I-DNA
vectors	I-DNA
re-establishes	O
or	O
substantially	O
enhances	O
class	O
II	O
inducibility	O
.	O


Nuclear	O
matrix-bound	O
RB	B-protein
was	O
detectable	O
in	O
all	O
cases	O
,	O
indicating	O
that	O
loss	O
of	O
RB	B-protein
is	O
not	O
responsible	O
for	O
decreased	O
class	O
II	O
expression	O
in	O
these	O
lines	O
.	O


CIITA	B-RNA
mRNA	I-RNA
is	O
normally	O
inducible	O
by	O
IFN-gamma	B-protein
in	O
class	B-cell_line
II	I-cell_line
non-inducible	I-cell_line
,	I-cell_line
RB-defective	I-cell_line
lines	I-cell_line
,	O
and	O
in	O
one	O
line	O
,	O
re-expression	O
of	O
RB	B-protein
has	O
no	O
effect	O
on	O
CIITA	B-RNA
mRNA	I-RNA
induction	O
levels	O
.	O


Interleukin	B-protein
12	I-protein
induces	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
STAT4	B-protein
in	O
human	B-cell_type
lymphocytes	I-cell_type
.	O


Recently	O
,	O
transcription	B-protein
factors	I-protein
known	O
as	O
STATs	B-protein
(	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
)	O
have	O
been	O
shown	O
to	O
be	O
tyrosine	O
phosphorylated	O
and	O
activated	O
in	O
response	O
to	O
a	O
number	O
of	O
cytokines	B-protein
that	O
bind	O
hematopoietin	B-protein
receptors	I-protein
and	O
activate	O
JAK	B-protein
kinases	I-protein
.	O


Furthermore	O
,	O
we	O
show	O
that	O
IL-12	B-protein
stimulates	O
formation	O
of	O
a	O
DNA-binding	B-protein
complex	I-protein
that	O
recognizes	O
a	O
DNA	O
sequence	O
previously	O
shown	O
to	O
bind	O
STAT	B-protein
proteins	I-protein
and	O
that	O
this	O
complex	O
contains	O
STAT4	B-protein
.	O


Temperature-induced	O
down-regulation	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
leucocyte	I-cell_type
in	O
patients	O
with	O
sepsis	O
or	O
septic	O
shock	O
.	O


We	O
have	O
studied	O
the	O
adaptive	O
mechanisms	O
which	O
occur	O
at	O
the	O
level	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
in	O
glucocorticoid	O
target	O
tissues	O
in	O
patients	O
with	O
sepsis	O
or	O
septic	O
shock	O
.	O


RESULTS	O
:	O
Hypercortisolaemia	O
,	O
in	O
vitro	O
,	O
resulted	O
in	O
a	O
decreased	O
affinity	O
and	O
a	O
decreased	O
binding	O
capacity	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
.	O


There	O
was	O
a	O
weak	O
but	O
significant	O
negative	O
correlation	O
between	O
body	O
temperature	O
and	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
the	O
patient	O
group	O
.	O


CONCLUSIONS	O
:	O
There	O
is	O
no	O
obvious	O
regulation	O
of	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
by	O
plasma	O
cortisol	O
concentrations	O
in	O
vivo	O
.	O


Activation	O
of	O
cytoplasmic	B-protein
tyrosine	I-protein
kinases	I-protein
is	O
an	O
important	O
aspect	O
of	O
signal	O
transduction	O
mediated	O
by	O
integrins	B-protein
.	O


In	O
addition	O
,	O
integrin	B-protein
ligation	O
leads	O
to	O
nuclear	O
translocation	O
of	O
the	O
p50	B-protein
and	O
p65	B-protein
subunits	I-protein
of	O
the	O
NF-kappa	B-protein
B	I-protein
transcription	I-protein
factor	I-protein
,	O
to	O
activation	O
of	O
a	O
reporter	B-DNA
gene	I-DNA
driven	O
by	O
a	O
promoter	B-DNA
containing	O
NF-kappa	B-DNA
B	I-DNA
sites	I-DNA
,	O
and	O
to	O
increased	O
levels	O
of	O
mRNAs	B-RNA
for	O
immediate-early	B-DNA
genes	I-DNA
,	O
including	O
the	O
cytokine	B-protein
interleukin	I-protein
(	I-protein
IL	I-protein
)	I-protein
-1	I-protein
beta	I-protein
.	O


In	O
adhering	B-cell_type
cells	I-cell_type
,	O
pre-treatment	O
with	O
cytochalasin	O
D	O
suppresses	O
tyrosine	O
phosphorylation	O
of	O
FAK	B-protein
and	O
paxillin	B-protein
but	O
not	O
of	O
Syk	B-protein
,	O
while	O
IL-1	B-protein
beta	I-protein
message	O
induction	O
is	O
unaffected	O
.	O


To	O
determine	O
if	O
New	O
World	O
primates	O
express	O
an	O
inhibitor	O
that	O
influences	O
glucocorticoid	B-protein
receptor	I-protein
(	O
GR	B-protein
)	O
binding	O
characteristics	O
,	O
we	O
examined	O
[	O
3H	O
]	O
dexamethasone	O
binding	O
in	O
cytosol	O
prepared	O
from	O
B95-8	B-cell_line
lymphoid	I-cell_line
cells	I-cell_line
,	O
derived	O
from	O
the	O
cotton	O
top	O
tamarin	O
(	O
Saguinus	O
oedipus	O
)	O
,	O
in	O
combination	O
with	O
cytosol	O
prepared	O
from	O
human	O
or	O
rat	O
tissues	O
.	O


The	O
inhibitory	O
activity	O
was	O
heat	O
labile	O
and	O
trypsin	B-protein
sensitive	O
.	O


These	O
data	O
demonstrate	O
that	O
B95-8	B-cell_type
cells	I-cell_type
contain	O
a	O
competitive	O
inhibitor	O
that	O
prevents	O
binding	O
of	O
dexamethasone	O
to	O
its	O
cognate	B-protein
receptor	I-protein
.	O


Here	O
,	O
we	O
show	O
that	O
the	O
Duffy	B-DNA
antigen/chemokine	I-DNA
receptor	I-DNA
gene	I-DNA
(	O
DARC	B-DNA
)	O
is	O
composed	O
of	O
a	O
single	O
exon	B-DNA
and	O
that	O
most	O
Duffy-negative	O
blacks	O
carry	O
a	O
silent	B-DNA
FY*B	I-DNA
allele	I-DNA
with	O
a	O
single	O
T	O
to	O
C	O
substitution	O
at	O
nucleotide	O
-46	O
.	O


The	O
present	O
studies	O
have	O
examined	O
the	O
effects	O
of	O
pokeweed	B-protein
mitogen	I-protein
(	O
PWM	B-protein
)	O
on	O
the	O
induction	O
of	O
early	B-DNA
growth	I-DNA
response-1	I-DNA
gene	I-DNA
(	O
EGR-1	B-DNA
)	O
in	O
normal	B-cell_type
human	I-cell_type
B	I-cell_type
cells	I-cell_type
.	O


Transient	O
transfection	O
assays	O
with	O
EGR-1	B-DNA
promoter	I-DNA
fragments	I-DNA
linked	O
to	O
the	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
gene	I-DNA
demonstrated	O
that	O
PWM	B-protein
induced	O
EGR-1	B-DNA
transcription	O
is	O
conferred	O
by	O
the	O
CArG	B-DNA
motif	I-DNA
(	O
C	B-DNA
C	I-DNA
[	I-DNA
AT	I-DNA
]	I-DNA
6GG	I-DNA
)	O
in	O
the	O
EGR-1	B-DNA
promoter	I-DNA
.	O


A	O
conserved	B-DNA
motif	I-DNA
in	O
the	O
promoters	B-DNA
of	O
several	O
cytokines	B-protein
expressed	O
by	O
human	B-cell_line
Th2-type	I-cell_line
lymphocytes	I-cell_line
.	O


It	O
contains	O
a	O
core	B-DNA
sequence	I-DNA
CTTGG	O
...	O
CCAAG	O
which	O
is	O
present	O
as	O
part	O
of	O
larger	O
palindromic	B-DNA
sequences	I-DNA
in	O
each	O
gene	O
.	O


This	O
suggest	O
that	O
they	O
may	O
interact	O
with	O
a	O
new	O
family	O
of	O
trans-acting	B-protein
factors	I-protein
.	O


Considering	O
the	O
strong	O
positive	O
regulatory	O
effect	O
of	O
this	O
element	B-DNA
and	O
its	O
presence	O
in	O
several	O
T-cell-expressed	B-DNA
cytokine	I-DNA
genes	I-DNA
,	O
it	O
may	O
be	O
crucial	O
to	O
the	O
coordinated	O
expression	O
of	O
these	O
cytokines	B-protein
in	O
T	B-cell_type
helper	I-cell_type
cells	I-cell_type
.	O


A	O
human	B-cell_line
T	I-cell_line
lymphoid	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
PEER	B-cell_line
,	O
dies	O
by	O
apoptosis	O
in	O
the	O
presence	O
of	O
PMA	O
and	O
calcium	O
ionophore	O
.	O


A	O
new	O
gene	B-DNA
,	O
TINUR	B-DNA
,	O
was	O
cloned	O
from	O
apoptotic	B-cell_line
PEER	I-cell_line
cells	I-cell_line
.	O


TINUR	B-DNA
belongs	O
to	O
the	O
NGFI-B/nur77	B-protein
family	I-protein
of	O
the	O
steroid	B-protein
receptor	I-protein
superfamily	I-protein
and	O
is	O
an	O
orphan	B-protein
receptor	I-protein
.	O


BACKGROUND	O
:	O
The	O
induction	O
of	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	I-protein
(	O
VCAM-1	B-protein
)	O
and	O
E-selectin	B-protein
by	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF	B-protein
)	O
is	O
mediated	O
by	O
mobilization	O
of	O
the	O
transcription	B-protein
factor	I-protein
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
.	O


Since	O
salicylates	O
have	O
been	O
reported	O
to	O
inhibit	O
NF-kappa	B-protein
B	I-protein
activation	O
by	O
preventing	O
the	O
degradation	O
of	O
its	O
inhibitor	O
I	B-protein
kappa	I-protein
B	I-protein
,	O
we	O
studied	O
a	O
potential	O
inhibition	O
of	O
this	O
pathway	O
by	O
acetylsalicylate	O
(	O
aspirin	O
)	O
in	O
human	B-cell_line
umbilical	I-cell_line
vein	I-cell_line
endothelial	I-cell_line
cells	I-cell_line
(	O
HUVECs	B-cell_line
)	O
.	O


Induction	O
of	O
VCAM-1	B-protein
and	O
E-selectin	B-protein
surface	O
expression	O
by	O
TNF	B-protein
was	O
dose-dependently	O
reduced	O
by	O
aspirin	O
over	O
the	O
same	O
range	O
,	O
while	O
induction	O
of	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
(	O
ICAM-1	B-protein
)	O
was	O
hardly	O
affected	O
.	O


Activation	O
of	O
NF-kappa	B-protein
B	I-protein
by	O
phosphatase	B-protein
inhibitors	O
involves	O
the	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
at	O
phosphatase	B-protein
2A-sensitive	I-protein
sites	I-protein
.	O


In	O
the	O
present	O
study	O
,	O
the	O
role	O
of	O
serine/threonine	B-protein
phosphatases	I-protein
in	O
the	O
regulation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
phosphorylation	O
was	O
investigated	O
.	O


Our	O
studies	O
demonstrate	O
that	O
incubation	O
of	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
with	O
low	O
concentrations	O
(	O
approximately	O
1-5	O
nM	O
)	O
of	O
calyculin	O
A	O
or	O
okadaic	O
acid	O
,	O
potent	O
inhibitors	O
of	O
protein	B-protein
phosphatase	I-protein
type	I-protein
1	I-protein
(	I-protein
PP-1	I-protein
)	I-protein
and	I-protein
type	I-protein
2A	I-protein
(	O
PP-2A	B-protein
)	O
,	O
induces	O
the	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
even	O
in	O
the	O
absence	O
of	O
any	O
cellular	O
stimulus	O
.	O


Furthermore	O
,	O
the	O
phosphorylated	B-protein
I	I-protein
kappa	I-protein
B	I-protein
alpha	I-protein
from	O
calyculin	B-cell_line
A-treated	I-cell_line
cells	I-cell_line
,	O
but	O
not	O
that	O
from	O
TNF-alpha-stimulated	B-cell_line
cells	I-cell_line
,	O
is	O
sensitive	O
to	O
PP-2A	B-protein
in	O
vitro	O
,	O
suggesting	O
the	O
existence	O
of	O
fundamental	O
differences	O
in	O
the	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
induced	O
by	O
the	O
two	O
different	O
NF-kappa	B-protein
B	I-protein
inducers	O
.	O


Together	O
,	O
these	O
results	O
suggest	O
that	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
,	O
mediated	O
through	O
both	O
the	O
TNF-alpha	B-protein
-inducible	O
and	O
the	O
PP-2A-opposing	B-protein
kinases	I-protein
,	O
may	O
serve	O
to	O
target	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
for	O
proteasome	B-protein
-mediated	O
degradation	O
.	O


Sp1	B-protein
functions	O
in	O
a	O
chromatin	B-DNA
-dependent	O
manner	O
to	O
augment	O
human	B-DNA
alpha-globin	I-DNA
promoter	I-DNA
activity	O
.	O


We	O
investigated	O
the	O
role	O
of	O
this	O
G	B-DNA
+	I-DNA
C-rich	I-DNA
region	I-DNA
in	O
augmenting	O
alpha-globin	B-DNA
promoter	I-DNA
activity	O
in	O
the	O
presence	O
of	O
the	O
far-upstream	B-DNA
alpha-globin	I-DNA
enhancer	I-DNA
,	O
HS-40	B-DNA
.	O


These	O
results	O
suggest	O
that	O
the	O
alpha-globin	B-DNA
G	I-DNA
+	I-DNA
C-rich	I-DNA
5	I-DNA
'	I-DNA
flanking	I-DNA
region	I-DNA
augments	O
alpha-globin	B-DNA
promoter	I-DNA
activity	O
in	O
a	O
chromatin	B-DNA
-dependent	O
manner	O
.	O


We	O
have	O
earlier	O
shown	O
that	O
stimulation	O
of	O
human	B-cell_line
CD4+	I-cell_line
T	I-cell_line
cells	I-cell_line
with	O
SEA	O
presented	O
on	O
Chinese	B-cell_line
hamster	I-cell_line
ovary	I-cell_line
(	I-cell_line
CHO	I-cell_line
)	I-cell_line
-DR	I-cell_line
transfectants	I-cell_line
coexpressing	O
either	O
B7	B-protein
or	O
LFA-3	B-protein
resulted	O
in	O
distinct	O
cytokine	B-protein
profiles	O
.	O


LFA-3	B-protein
induced	O
moderate	O
levels	O
of	O
AP-1	B-protein
,	O
but	O
did	O
not	O
influence	O
the	O
levels	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
while	O
B7	B-protein
costimulation	O
strongly	O
induced	O
both	O
AP-1	B-protein
and	O
substantially	O
enhanced	O
NF-kappa	B-protein
B	I-protein
binding	I-protein
proteins	I-protein
.	O


The	O
CHO-DR/B7/LFA-3	B-cell_line
triple	I-cell_line
transfectant	I-cell_line
induced	O
a	O
further	O
increase	O
in	O
AP-1	B-protein
and	O
NF-kappa	B-protein
B	I-protein
binding	B-protein
proteins	I-protein
compared	O
with	O
the	O
double	B-cell_line
transfectants	I-cell_line
.	O


The	O
AP-1	B-protein
binding	I-protein
proteins	I-protein
contained	O
c-Jun	B-protein
,	O
Jun-D	B-protein
,	O
and	O
Fra-1	B-protein
,	O
but	O
marginal	O
amounts	O
of	O
Jun-B	B-protein
and	O
c-Fos	B-protein
.	O


The	O
Ah	B-protein
receptor	I-protein
recognizes	O
DNA	B-DNA
binding	I-DNA
sites	I-DNA
for	O
the	O
B	B-protein
cell	I-protein
transcription	I-protein
factor	I-protein
,	O
BSAP	B-protein
:	O
a	O
possible	O
mechanism	O
for	O
dioxin-mediated	O
alteration	O
of	O
CD19	B-DNA
gene	I-DNA
expression	O
in	O
human	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O


Using	O
a	O
gel	O
mobility	O
shift	O
assay	O
,	O
we	O
identified	O
a	O
DNA-binding	B-protein
complex	I-protein
in	O
IM-9	O
nuclear	O
extracts	O
that	O
by	O
several	O
criteria	O
appears	O
to	O
be	O
the	O
Ah	B-protein
receptor	I-protein
.	O


These	O
results	O
suggest	O
that	O
the	O
AhR	B-protein
could	O
interfere	O
with	O
BSAP	B-protein
-stimulated	O
CD19	B-DNA
gene	I-DNA
transcription	O
by	O
competition	O
for	O
a	O
common	O
DNA	B-DNA
binding	I-DNA
site	I-DNA
.	O


We	O
recently	O
identified	O
a	O
differentiation	B-protein
inhibitory	I-protein
factor	I-protein
(	O
I-factor	B-protein
)	O
in	O
mouse	B-cell_line
myeloid	I-cell_line
leukemia	I-cell_line
M1	I-cell_line
cells	I-cell_line
as	O
a	O
murine	B-protein
homolog	I-protein
of	O
the	O
human	B-protein
nm23-H2	I-protein
gene	I-protein
product	I-protein
.	O


In	O
the	O
present	O
experiment	O
,	O
we	O
examined	O
the	O
effect	O
of	O
nm23	B-protein
proteins	I-protein
on	O
various	O
differentiation	O
induction	O
systems	O
of	O
human	B-cell_type
leukemic	I-cell_type
cells	I-cell_type
including	O
HL-60	B-cell_line
,	I-cell_line
U937	I-cell_line
,	I-cell_line
HEL/S	I-cell_line
,	I-cell_line
KU812F	I-cell_line
,	I-cell_line
K562	I-cell_line
,	I-cell_line
and	I-cell_line
HEL	I-cell_line
cells	I-cell_line
.	O


The	O
erythroid	O
differentiation	O
of	O
HEL	B-cell_line
cells	I-cell_line
was	O
inhibited	O
by	O
recombinant	B-protein
human	I-protein
nm23-H1	I-protein
,	I-protein
-H2	I-protein
,	I-protein
mouse	I-protein
nm23-M1	I-protein
,	I-protein
and	I-protein
-M2	I-protein
proteins	I-protein
.	O


These	O
results	O
suggest	O
that	O
(	O
1	O
)	O
the	O
differentiation	O
inhibitory	O
activity	O
of	O
I-factor/nm23	B-protein
protein	I-protein
is	O
not	O
restricted	O
to	O
monocytic	O
differentiation	O
of	O
M1	B-cell_line
cells	I-cell_line
,	O
(	O
2	O
)	O
the	O
inhibitory	O
activity	O
is	O
exhibited	O
without	O
species	O
specificity	O
,	O
and	O
(	O
3	O
)	O
the	O
differentiation	O
inhibitory	O
activity	O
of	O
the	O
nm23/NDP	B-protein
kinase	I-protein
protein	I-protein
is	O
independent	O
of	O
its	O
enzyme	O
activity	O
and	O
requires	O
the	O
presence	O
of	O
N-terminal	O
peptides	O
.	O


Lipopolysaccharide-induced	O
E-selectin	B-protein
expression	O
requires	O
continuous	O
presence	O
of	O
LPS	O
and	O
is	O
inhibited	O
by	O
bactericidal/permeability-increasing	B-protein
protein	I-protein
.	O


Endothelial	B-cell_type
cells	I-cell_type
stimulated	O
by	O
LPS	O
express	O
E-selectin	B-protein
,	O
which	O
plays	O
an	O
important	O
role	O
in	O
mediating	O
neutrophil	B-cell_type
adhesion	O
during	O
inflammation	O
.	O


rBPI21	B-protein
,	O
a	O
recombinant	B-protein
N-terminal	I-protein
fragment	I-protein
of	O
human	B-protein
bactericidal/permeability-increasing	I-protein
protein	I-protein
(	O
BPI	B-protein
)	O
,	O
inhibited	O
LPS-induced	O
E-selectin	B-protein
expression	O
when	O
added	O
at	O
the	O
same	O
time	O
as	O
,	O
and	O
up	O
to	O
6	O
h	O
after	O
,	O
LPS	O
.	O


GM-CSF	B-protein
and	O
IL-2	B-protein
share	O
common	O
control	O
mechanisms	O
in	O
response	O
to	O
costimulatory	O
signals	O
in	O
T	B-cell_type
cells	I-cell_type
.	O


High	O
levels	O
of	O
cytokine	B-protein
gene	O
expression	O
in	O
T	B-cell_type
cells	I-cell_type
also	O
required	O
both	O
TCR	B-protein
and	O
costimulatory	O
signals	O
.	O


These	O
promoter	B-DNA
and	I-DNA
enhancer	I-DNA
regions	I-DNA
are	O
mainly	O
activated	O
by	O
the	O
transcription	B-protein
factor	I-protein
nuclear	I-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NFAT	B-protein
)	O
.	O


Human	O
T	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
infects	O
T	B-cell_type
cells	I-cell_type
and	O
can	O
lead	O
to	O
increase	O
GM-CSF	B-protein
expression	O
.	O


We	O
have	O
found	O
that	O
the	O
HTLV-1	B-protein
transactivator	I-protein
protein	I-protein
,	O
tax	B-protein
,	O
acts	O
as	O
a	O
costimulatory	O
signal	O
for	O
GM-CSF	O
and	O
IL-2	O
gene	O
transcription	O
,	O
in	O
that	O
it	O
can	O
cooperate	O
with	O
TCR	B-protein
signals	O
to	O
mediate	O
high	O
level	O
gene	O
expression	O
.	O


Tax	O
activates	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
through	O
the	O
CK-1	B-DNA
/CD28RE	B-DNA
region	O
and	O
also	O
activates	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
binding	O
to	O
this	O
region	O
.	O


3.	O
Danazol	O
decreased	O
the	O
transcription	O
rate	O
of	O
ER	B-DNA
gene	I-DNA
to	O
approximately	O
50	O
%	O
in	O
monocytes	B-cell_type
in	O
a	O
run-on	O
assay	O
.	O


4.	O
Danazol	O
may	O
release	O
estrogen	O
predominance	O
via	O
the	O
reduction	O
of	O
transcription	O
for	O
ER	B-DNA
gene	I-DNA
,	O
which	O
leads	O
to	O
the	O
reduction	O
of	O
ER	B-RNA
mRNA	I-RNA
and	O
ER	B-protein
expressions	O
in	O
monocytes	B-cell_type
.	O


IL-2	B-protein
-mediated	O
T	B-cell_type
cell	I-cell_type
proliferation	O
is	O
a	O
critical	O
early	O
event	O
in	O
the	O
inflammatory	O
process	O
.	O


Both	O
compounds	O
inhibited	O
the	O
mixed	O
lymphocyte	O
reaction	O
,	O
and	O
this	O
inhibition	O
was	O
reversed	O
by	O
exogenous	O
IL-2	B-protein
.	O


Conversely	O
,	O
calcium-independent	B-protein
anti-CD28	I-protein
Ab	I-protein
and	O
PMA-induced	O
IL-2	B-protein
production	O
was	O
resistant	O
.	O


By	O
these	O
functional	O
criteria	O
,	O
we	O
believe	O
we	O
have	O
identified	O
two	O
structurally	O
distinct	O
,	O
novel	O
inhibitors	O
of	O
NFAT	B-protein
-1-mediated	O
transcription	O
.	O


We	O
examined	O
mRNA	B-RNA
levels	O
of	O
various	O
V-ATPase	B-protein
subunits	O
during	O
differentiation	O
of	O
both	O
native	B-cell_type
monocytes	I-cell_type
and	O
the	O
cell	B-cell_line
line	I-cell_line
THP-1	B-cell_line
,	O
and	O
found	O
that	O
transcriptional	O
and	O
post-transcriptional	O
mechanisms	O
could	O
account	O
for	O
increases	O
in	O
cell	O
V-ATPase	B-protein
content	O
.	O


From	O
nuclear	O
runoff	O
experiments	O
,	O
we	O
found	O
that	O
one	O
subunit	O
in	O
particular	O
,	O
the	O
B2	B-protein
isoform	I-protein
(	O
Mr	O
=	O
56	O
,	O
000	O
)	O
,	O
was	O
amplified	O
primarily	O
by	O
transcriptional	O
means	O
.	O


We	O
have	O
begun	O
to	O
examine	O
the	O
structure	O
of	O
the	O
B2	B-DNA
subunit	I-DNA
promoter	I-DNA
region	I-DNA
.	O


Primer	O
extension	O
and	O
ribonuclease	B-protein
protection	O
analyses	O
indicate	O
a	O
single	O
major	B-DNA
transcriptional	I-DNA
start	I-DNA
site	I-DNA
.	O


Synergy	O
between	O
signal	O
transduction	O
pathways	O
is	O
obligatory	O
for	O
expression	O
of	O
c-fos	B-DNA
in	O
B	B-cell_line
and	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
:	O
implication	O
for	O
c-fos	B-DNA
control	O
via	O
surface	B-protein
immunoglobulin	I-protein
and	O
T	B-protein
cell	I-protein
antigen	I-protein
receptors	I-protein
.	O


Kinase	B-protein
C	I-protein
mediates	O
its	O
effects	O
via	O
phosphorylation	O
of	O
serum	B-protein
response	I-protein
factor	I-protein
(	O
SRF	B-protein
)	O
which	O
interacts	O
with	O
the	O
serum	B-DNA
response	I-DNA
element	I-DNA
(	O
SRE	B-DNA
)	O
;	O
cAMP	O
and	O
calcium	O
mediate	O
their	O
effects	O
via	O
phosphorylation	O
of	O
CREB	B-protein
(	O
cAMP	B-protein
regulatory	I-protein
element	I-protein
binding	I-protein
protein	I-protein
)	O
presumably	O
by	O
activation	O
of	O
a	O
protein	B-protein
kinase	I-protein
A	I-protein
or	O
calmodulin-regulated	B-protein
kinase	I-protein
.	O


We	O
have	O
found	O
that	O
stimulation	O
of	O
any	O
one	O
of	O
these	O
pathways	O
alone	O
has	O
little	O
or	O
no	O
effect	O
on	O
c-fos	B-DNA
induction	O
.	O


Our	O
results	O
indicate	O
that	O
synergy	O
between	O
the	O
kinase	B-protein
C	I-protein
activation	O
and	O
calcium	O
is	O
needed	O
for	O
efficient	O
c-fos	B-DNA
induction	O
since	O
neither	O
of	O
these	O
two	O
alone	O
induces	O
c-fos	B-DNA
well	O
.	O


These	O
results	O
suggest	O
that	O
cell-specific	O
patterns	O
of	O
synergy	O
are	O
an	O
essential	O
feature	O
for	O
c-fos	B-DNA
induction	O
and	O
may	O
be	O
relevant	O
for	O
c-fos	B-DNA
control	O
through	O
B	B-protein
and	I-protein
T	I-protein
cell	I-protein
antigen	I-protein
receptors	I-protein
.	O


Multiple	O
signals	O
are	O
required	O
for	O
function	O
of	O
the	O
human	B-DNA
granulocyte-macrophage	I-DNA
colony-stimulating	I-DNA
factor	I-DNA
gene	I-DNA
promoter	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
.	O


The	O
gene	O
contains	O
a	O
proximal	B-DNA
functional	I-DNA
promoter	I-DNA
region	I-DNA
(	O
-620	B-DNA
to	I-DNA
+34	I-DNA
)	O
,	O
as	O
well	O
as	O
a	O
powerful	O
enhancer	B-DNA
located	O
3	O
kb	O
upstream	O
,	O
both	O
of	O
which	O
are	O
involved	O
in	O
the	O
response	O
of	O
the	O
gene	O
to	O
TCR	B-protein
activation	O
.	O


The	O
proximal	B-DNA
promoter	I-DNA
contains	O
a	O
region	O
termed	O
CLEO	B-DNA
(	O
-54	B-DNA
to	I-DNA
-31	I-DNA
)	O
that	O
consists	O
of	O
a	O
purine-rich	B-DNA
element	I-DNA
abutting	O
an	O
activator	B-DNA
protein-1	I-DNA
(	I-DNA
AP-1	I-DNA
)	I-DNA
-like	I-DNA
site	I-DNA
,	O
as	O
well	O
as	O
an	O
upstream	B-DNA
nuclear	I-DNA
factor-kappa	I-DNA
B	I-DNA
(	I-DNA
NF-kappa	I-DNA
B	I-DNA
)	I-DNA
site	I-DNA
(	O
-85	B-DNA
to	I-DNA
-76	I-DNA
)	O
and	O
a	O
CK-1	B-DNA
element	I-DNA
(	O
-101	B-DNA
to	I-DNA
-92	I-DNA
)	O
.	O


A	O
second	O
weak	O
inducible	O
complex	O
resembling	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NF-AT	B-protein
)	O
was	O
also	O
observed	O
binding	O
to	O
the	O
hCLEO	B-DNA
region	I-DNA
.	O


We	O
found	O
that	O
expression	O
of	O
a	O
constitutively	O
active	O
form	O
of	O
calcineurin	B-protein
could	O
substitute	O
for	O
Ca2+	O
ionophore	O
and	O
synergize	O
with	O
PMA	O
to	O
activate	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
,	O
and	O
conversely	O
that	O
mutant-activated	B-protein
Ras	I-protein
could	O
substitute	O
for	O
PMA	O
and	O
cooperate	O
with	O
Ca2+	O
ionophore	O
.	O


These	O
results	O
imply	O
that	O
at	O
least	O
three	O
signals	O
are	O
required	O
to	O
activate	O
the	O
GM-CSF	B-DNA
proximal	I-DNA
promoter	I-DNA
,	O
and	O
that	O
the	O
signals	O
impinge	O
on	O
distinct	O
transcription	B-protein
factors	I-protein
that	O
bind	O
to	O
the	O
hCLEO	B-DNA
and	I-DNA
NF-kappa	I-DNA
B	I-DNA
regions	I-DNA
of	O
the	O
promoter	B-DNA
.	O


IL-10	B-protein
affects	O
monocytes	B-cell_type
and	O
T	B-cell_type
cells	I-cell_type
by	O
driving	O
the	O
progression	O
of	O
immune	O
responsiveness	O
such	O
that	O
Th2	O
lymphocyte-mediated	O
effects	O
predominate	O
.	O


Moreover	O
,	O
monocytes	B-cell_type
express	O
a	O
novel	O
IL-10-stimulated	B-protein
STAT	I-protein
protein	I-protein
with	O
an	O
M	O
(	O
r	O
)	O
of	O
70	B-protein
kDa	I-protein
that	O
is	O
recognized	O
by	O
the	O
anti-STAT3	B-protein
Ab	I-protein
but	O
is	O
not	O
observed	O
in	O
T	B-cell_type
cells	I-cell_type
.	O


All	O
the	O
markers	O
considered	O
were	O
sufficiently	O
sensitive	O
,	O
but	O
among	O
them	O
,	O
Platelet	B-protein
Factor	I-protein
IV	I-protein
was	O
the	O
most	O
reliable	O
to	O
the	O
hormonal	O
ovulatory	O
situation	O
.	O


They	O
also	O
display	O
constitutively	O
high	O
levels	O
of	O
p59fyn	B-protein
and	O
CD3	B-protein
zeta	I-protein
tyrosine	O
phosphorylation	O
.	O


Upon	O
stimulation	O
with	O
mitogens	O
,	O
formation	O
of	O
the	O
transactivating	O
complex	O
,	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NF-AT	B-protein
)	O
,	O
occurs	O
with	O
normal	O
kinetics	O
in	O
Ipr	B-cell_line
CD4-8-	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O


Yet	O
,	O
the	O
levels	O
of	O
the	O
activating	O
NF-AT	B-protein
complex	I-protein
never	O
reach	O
those	O
observed	O
in	O
similarly	O
stimulated	O
normal	O
T	B-cell_type
cells	I-cell_type
.	O


Furthermore	O
,	O
nuclear	O
extracts	O
from	O
Ipr	B-cell_line
CD4-8-	I-cell_line
T	I-cell_line
cells	I-cell_line
display	O
high	O
levels	O
of	O
a	O
novel	O
specific	O
binding	O
activity	O
at	O
the	O
NF-AT	B-DNA
site	I-DNA
,	O
which	O
is	O
present	O
at	O
much	O
lower	O
levels	O
in	O
freshly	O
isolated	O
normal	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O


These	O
two	O
abnormalities	O
at	O
the	O
NF-AT	B-DNA
site	I-DNA
provide	O
a	O
potential	O
mechanism	O
to	O
account	O
for	O
the	O
defect	O
in	O
IL-2	B-protein
production	O
from	O
Ipr	B-cell_line
CD4-8-	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O


We	O
demonstrate	O
that	O
cross-linking	O
CD30	B-protein
with	O
an	O
anti-	O
CD30	B-protein
-specific	O
monoclonal	O
antibody	O
,	O
which	O
mimics	O
the	O
described	O
biological	O
activities	O
of	O
the	O
CD30	B-protein
ligand	I-protein
(	O
CD30L	B-protein
)	O
,	O
results	O
in	O
HIV	O
expression	O
.	O


Thus	O
,	O
CD30	B-protein
-CD30L	B-protein
interactions	O
mediate	O
the	O
induction	O
of	O
HIV	O
expression	O
by	O
a	O
kappa	O
B-dependent	O
pathway	O
that	O
is	O
independent	O
of	O
TNF	B-protein
.	O


Recently	O
,	O
the	O
defective	B-DNA
gene	I-DNA
in	O
group	O
II	O
type	O
II	O
MHC	B-protein
CID	O
has	O
been	O
isolated	O
and	O
termed	O
CIITA	B-DNA
.	O


The	O
transactivation	O
of	O
multiple	B-DNA
cis	I-DNA
elements	I-DNA
,	O
especially	O
S	B-DNA
and	O
X2	B-DNA
,	O
of	O
the	O
DR	B-DNA
alpha	I-DNA
proximal	I-DNA
promoter	I-DNA
in	O
group	B-cell_line
II	I-cell_line
CID	I-cell_line
cells	I-cell_line
is	O
CIITA	B-protein
dependent	O
.	O


Since	O
CIITA	B-protein
overexpression	O
in	O
normal	B-cell_type
cells	I-cell_type
did	O
not	O
increase	O
class	O
II	O
expression	O
,	O
we	O
propose	O
that	O
initiation	O
of	O
CIITA	B-protein
expression	O
serves	O
as	O
the	O
on-off	O
switch	O
,	O
while	O
availability	O
of	O
downstream	O
interactor	O
(	O
s	O
)	O
limits	O
transcription	O
.	O


Monocyte	O
tethering	O
by	O
P-selectin	B-protein
regulates	O
monocyte	B-protein
chemotactic	I-protein
protein-1	I-protein
and	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
secretion	O
.	O


Adhesion	O
of	O
human	B-cell_type
monocytes	I-cell_type
to	O
P-selectin	B-protein
,	O
the	O
most	O
rapidly	O
expressed	O
endothelial	B-protein
tethering	I-protein
factor	I-protein
,	O
increased	O
the	O
secretion	O
of	O
monocyte	B-protein
chemotactic	I-protein
protein-1	I-protein
(	O
MCP-1	B-protein
)	O
and	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
by	O
the	O
leukocytes	B-cell_type
when	O
they	O
were	O
stimulated	O
with	O
platelet-activating	B-protein
factor	I-protein
.	O


These	O
results	O
demonstrate	O
that	O
P-selectin	B-protein
,	O
through	O
its	O
ligands	O
on	O
monocytes	B-cell_type
,	O
may	O
locally	O
regulate	O
cytokine	B-protein
secretion	O
in	O
inflamed	O
tissues	O
.	O


Transcriptional	O
regulation	O
of	O
the	O
human	B-DNA
alpha-like	I-DNA
globin	I-DNA
genes	I-DNA
,	O
embryonic	B-DNA
zeta	I-DNA
2	I-DNA
and	O
adult	B-DNA
alpha	I-DNA
,	O
during	O
erythroid	O
development	O
is	O
mediated	O
by	O
a	O
distal	B-DNA
enhancer	I-DNA
,	O
HS-40	B-DNA
.	O


On	O
the	O
other	O
hand	O
,	O
the	O
3'NF-E2/AP1	B-DNA
motif	I-DNA
is	O
able	O
to	O
exert	O
both	O
positive	O
and	O
negative	O
regulatory	O
effects	O
on	O
the	O
zeta	B-DNA
2-globin	I-DNA
promoter	I-DNA
activity	O
in	O
K562	B-cell_line
cells	I-cell_line
,	O
and	O
this	O
dual	O
function	O
appears	O
to	O
be	O
modulated	O
through	O
differential	O
binding	O
of	O
the	O
ubiquitous	B-protein
AP1	I-protein
factors	I-protein
and	O
the	O
erythroid-enriched	B-protein
NF-E2	I-protein
factor	I-protein
.	O


Nitric	O
oxide-stimulated	O
guanine	O
nucleotide	O
exchange	O
on	O
p21ras	B-protein
.	O


Circular	O
dichroism	O
analysis	O
reveals	O
that	O
NO	O
induces	O
a	O
profound	O
conformational	O
change	O
in	O
p21ras	B-DNA
in	O
association	O
with	O
GDP/GTP	O
exchange	O
.	O


Furthermore	O
,	O
we	O
demonstrate	O
that	O
p21ras	B-protein
is	O
essential	O
for	O
NO-induced	O
downstream	O
signaling	O
,	O
such	O
as	O
NF-kappa	B-protein
B	I-protein
activation	O
,	O
and	O
that	O
endogenous	O
NO	O
can	O
activate	O
p21ras	B-protein
in	O
the	O
same	O
cell	O
.	O


These	O
studies	O
identify	O
p21ras	B-DNA
as	O
a	O
target	O
of	O
NO	O
in	O
T	B-cell_type
cells	I-cell_type
and	O
suggest	O
that	O
NO	O
activates	O
p21ras	B-DNA
by	O
an	O
action	O
which	O
mimics	O
that	O
of	O
guanine	B-protein
nucleotide	I-protein
exchange	I-protein
factors	I-protein
.	O


Transient	O
transfections	O
using	O
reporter	B-DNA
constructs	I-DNA
with	O
multiples	O
of	O
transcription	B-DNA
factor	I-DNA
binding	I-DNA
sites	I-DNA
from	O
the	O
IL-2	B-DNA
promoter	I-DNA
[	O
distal	B-protein
nuclear	I-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-AT	I-protein
,	O
proximal	B-protein
NF-AT	I-protein
,	O
AP-1/Octamer	B-protein
(	O
UPS	B-protein
)	O
or	O
NF-chi	B-protein
B	I-protein
(	O
TCEd	B-protein
)	O
sites	O
]	O
were	O
performed	O
.	O


Similarly	O
,	O
a	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
promoter	I-DNA
,	O
whose	O
activity	O
is	O
controlled	O
through	O
chi	B-protein
B	I-protein
factors	I-protein
,	O
was	O
found	O
to	O
be	O
active	O
in	O
the	O
IL-2	B-cell_line
producing	I-cell_line
EBV-B	I-cell_line
cells	I-cell_line
,	O
but	O
inactive	O
in	O
the	O
non-IL-2-producing	B-cell_line
cells	I-cell_line
.	O


Electrophoretic	O
mobility	O
shift	O
assays	O
using	O
protein	O
extracts	O
from	O
EBV-B	B-cell_line
cells	I-cell_line
and	O
the	O
IL-2	B-protein
NF-chi	B-protein
B	I-protein
probe	O
revealed	O
the	O
constitutive	O
generation	O
of	O
chi	B-protein
B	I-protein
complexes	I-protein
in	O
IL-2-secreting	B-cell_line
cells	I-cell_line
consisting	O
mainly	O
of	O
heterodimeric	B-protein
p50/p65	I-protein
complexes	I-protein
.	O


These	O
regulators	O
are	O
targeted	O
by	O
negative	O
growth	O
regulatory	O
signals	O
,	O
such	O
as	O
that	O
provided	O
by	O
TGF-beta	B-protein
.	O


Here	O
,	O
we	O
show	O
that	O
the	O
presence	O
of	O
either	O
wild-type	O
EBV	O
or	O
its	O
transforming	B-protein
latent	I-protein
membrane	I-protein
protein-1	I-protein
(	O
LMP-1	B-protein
)	O
results	O
in	O
the	O
loss	O
of	O
TGF-beta	B-protein
1	I-protein
-mediated	O
growth	O
inhibition	O
in	O
human	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O


Chemical	O
cross-linking	O
with	O
125I-labeled	B-protein
TGF-beta	I-protein
1	I-protein
showed	O
an	O
essentially	O
normal	O
TGF-beta	B-protein
receptor	I-protein
profile	O
in	O
EBV-positive	B-cell_line
and	I-cell_line
EBV-negative	I-cell_line
Burkitt	I-cell_line
's	I-cell_line
lymphoma	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
and	O
these	O
receptors	O
were	O
shown	O
to	O
be	O
functional	O
in	O
transducing	O
signals	O
,	O
as	O
evidenced	O
by	O
the	O
TGF-beta	B-protein
1	I-protein
-mediated	O
modulation	O
of	O
junB	B-DNA
gene	I-DNA
expression	O
.	O


Furthermore	O
,	O
LMP-1	B-protein
was	O
found	O
to	O
induce	O
the	O
expression	O
of	O
cyclin	B-protein
D2	I-protein
;	O
normal	O
B	B-cell_type
cells	I-cell_type
or	O
EBV-negative	B-cell_line
Burkitt	I-cell_line
's	I-cell_line
lymphoma	I-cell_line
cells	I-cell_line
do	O
not	O
express	O
D-type	B-protein
cyclins	I-protein
.	O


Reactivity	O
to	O
TSHR	B-protein
peptides	O
before	O
surgery	O
was	O
heterogeneous	O
and	O
spanned	O
the	O
entire	O
extracellular	B-protein
domain	I-protein
.	O


Six	O
to	O
8	O
weeks	O
after	O
subtotal	O
thyroidectomy	O
,	O
the	O
number	O
of	O
patients	O
'	O
PBMC	B-cell_type
responding	O
to	O
any	O
peptide	O
and	O
the	O
average	O
number	O
of	O
recognized	O
peptides	O
decreased	O
.	O


Three	O
to	O
6	O
months	O
after	O
RAI	O
,	O
T	O
cell	O
responses	O
to	O
TSHR	B-protein
peptides	O
were	O
less	O
than	O
those	O
6-8	O
weeks	O
after	O
RAI	O
therapy	O
,	O
but	O
still	O
higher	O
than	O
the	O
values	O
on	O
day	O
0	O
.	O


Responses	O
of	O
PBMC	B-cell_type
from	O
patients	O
with	O
GD	O
,	O
maintained	O
euthyroid	O
on	O
ATD	O
,	O
were	O
lower	O
than	O
those	O
before	O
surgery	O
or	O
RAI	O
therapy	O
.	O


The	O
reactivity	O
of	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
in	O
different	O
groups	O
reflected	O
a	O
pattern	O
similar	O
to	O
PBMC	B-cell_type
after	O
treatment	O
.	O


The	O
increased	O
T	O
cell	O
response	O
after	O
RAI	O
therapy	O
is	O
probably	O
epitope	O
specific	O
,	O
rather	O
than	O
a	O
response	O
to	O
the	O
whole	O
TSHR	B-protein
molecule	O
.	O


Circumvention	O
of	O
tolerance	O
for	O
the	O
nuclear	B-protein
T	I-protein
cell	I-protein
protein	I-protein
TCF-1	B-protein
by	O
immunization	O
of	O
TCF-1	B-protein
knock-out	O
mice	O
.	O


Molecular	O
events	O
that	O
underlie	O
the	O
well-defined	O
phenotypic	O
changes	O
of	O
the	O
differentiating	B-cell_type
thymocyte	I-cell_type
are	O
poorly	O
understood	O
.	O


A	O
candidate	O
gene	O
to	O
control	O
thymocyte	B-cell_type
differentiation	O
,	O
T	B-protein
cell	I-protein
factor-1	I-protein
(	O
TCF-1	B-protein
)	O
*	O
encodes	O
a	O
DNA-binding	B-protein
protein	I-protein
.	O


By	O
immunization	O
with	O
a	O
recombinant	B-protein
fusion	I-protein
protein	I-protein
,	O
we	O
show	O
that	O
TCF-1	B-protein
knock-out	O
mice	O
readily	O
yield	O
antiserum	O
titers	O
against	O
human	O
and	O
mouse	O
TCF-1	O
protein	O
.	O


Furthermore	O
,	O
the	O
usefulness	O
of	O
knock-out	O
mice	O
for	O
the	O
generation	O
of	O
monoclonal	B-protein
antibodies	I-protein
against	O
the	O
gene	O
product	O
of	O
interest	O
is	O
underscored	O
.	O


We	O
have	O
identified	O
an	O
in	O
vivo	O
footprint	O
over	O
the	O
PuF	B-DNA
site	I-DNA
on	O
the	O
translocated	O
c-myc	B-DNA
allele	I-DNA
in	O
Burkitt	O
's	O
lymphoma	O
cells	O
.	O


We	O
demonstrated	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
electrophoretic	O
mobility	O
shift	O
assay	O
with	O
antibody	O
,	O
UV	O
cross-linking	O
followed	O
by	O
SDS-gel	O
electrophoresis	O
,	O
and	O
Western	O
analysis	O
that	O
Nm23H2	B-protein
in	O
B	O
cell	O
nuclear	O
extracts	O
bound	O
to	O
the	O
c-myc	O
PuF	B-DNA
site	I-DNA
.	O


Identification	O
of	O
two	O
novel	O
regulatory	B-DNA
elements	I-DNA
within	O
the	O
5'-untranslated	B-DNA
region	I-DNA
of	O
the	O
human	B-DNA
A	I-DNA
gamma-globin	I-DNA
gene	I-DNA
.	O


We	O
have	O
now	O
demonstrated	O
that	O
a	O
second	O
SSE-like	B-DNA
element	I-DNA
in	O
the	O
5'-untranslated	B-DNA
region	I-DNA
of	O
the	O
gamma-gene	B-DNA
also	O
contributes	O
to	O
this	O
competitive	O
silencing	O
of	O
the	O
beta-gene	B-DNA
.	O


A	O
marked	O
activation	O
of	O
gamma-promoter	B-DNA
activity	O
was	O
also	O
observed	O
with	O
this	O
mutation	O
,	O
suggesting	O
the	O
presence	O
of	O
a	O
repressor	O
.	O


The	O
stage	O
selector	O
activity	O
was	O
localized	O
to	O
a	O
region	O
centered	O
on	O
nucleotides	B-DNA
+13	I-DNA
to	I-DNA
+15	I-DNA
.	O


The	O
repressor	O
activity	O
of	O
the	O
5'-UTR	B-DNA
was	O
localized	O
to	O
tandem	O
GATA-like	B-DNA
sites	I-DNA
,	O
which	O
appear	O
to	O
bind	O
a	O
complex	O
of	O
two	O
proteins	O
,	O
one	O
of	O
which	O
is	O
the	O
erythroid	B-protein
transcription	I-protein
factor	I-protein
GATA-1	B-protein
.	O


Coupling	O
of	O
a	O
signal	B-protein
response	I-protein
domain	I-protein
in	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
to	O
multiple	O
pathways	O
for	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O


The	O
nuclear	O
activity	O
of	O
NF-kappa	B-protein
B	I-protein
is	O
tightly	O
regulated	O
from	O
the	O
cytoplasmic	O
compartment	O
by	O
an	O
inhibitory	B-protein
subunit	I-protein
called	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O


To	O
explore	O
these	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
-dependent	O
mechanisms	O
for	O
NF-kappa	B-protein
B	I-protein
induction	O
,	O
we	O
identified	O
novel	O
mutants	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
that	O
uncouple	O
its	O
inhibitory	O
and	O
signal-transducing	O
functions	O
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O


Specifically	O
,	O
removal	O
of	O
the	O
N-terminal	B-protein
36	I-protein
amino	I-protein
acids	I-protein
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
failed	O
to	O
disrupt	O
its	O
ability	O
to	O
form	O
latent	O
complexes	O
with	O
NF-kappa	B-protein
B	I-protein
in	O
the	O
cytoplasm	O
.	O


However	O
,	O
this	O
deletion	O
mutation	O
prevented	O
the	O
induced	O
phosphorylation	O
,	O
degradative	O
loss	O
,	O
and	O
functional	O
release	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
from	O
NF-kappa	B-protein
B	I-protein
in	O
Tax-expressing	B-cell_line
cells	I-cell_line
.	O


In	O
contrast	O
,	O
introduction	O
of	O
a	O
phosphoserine	O
mimetic	O
at	O
these	O
sites	O
rectified	O
this	O
functional	O
defect	O
,	O
a	O
finding	O
consistent	O
with	O
a	O
causal	O
linkage	O
between	O
the	O
phosphorylation	O
status	O
and	O
proteolytic	O
stability	O
of	O
this	O
cytoplasmic	B-protein
inhibitor	I-protein
.	O


Growth	O
regulation	O
and	O
cellular	O
changes	O
during	O
differentiation	O
of	O
human	B-cell_line
prostatic	I-cell_line
cancer	I-cell_line
LNCaP	I-cell_line
cells	I-cell_line
as	O
induced	O
by	O
T	O
lymphocyte-conditioned	O
medium	O
.	O


The	O
binding	O
of	O
androgen	O
to	O
androgen	B-protein
receptor	I-protein
on	O
these	O
cells	O
showed	O
approximately	O
50	O
%	O
reduction	O
,	O
underlining	O
a	O
proliferation	O
reduction	O
mechanism	O
.	O


Activated	O
T	B-cell_type
cells	I-cell_type
were	O
demonstrated	O
to	O
be	O
important	O
in	O
providing	O
the	O
modulating	O
activity	O
.	O


This	O
growth	B-protein
modulator	I-protein
was	O
semipurified	O
and	O
had	O
an	O
estimated	O
molecular	O
weight	O
13	O
,	O
000	O
to	O
24	O
,	O
000	O
Da	O
.	O


Platelet-activating	B-protein
factor	I-protein
stimulates	O
transcription	O
of	O
the	O
heparin-binding	B-protein
epidermal	I-protein
growth	I-protein
factor-like	I-protein
growth	I-protein
factor	I-protein
in	O
monocytes	B-cell_type
.	O


This	O
function	O
of	O
PAF	B-protein
was	O
observed	O
at	O
nanomolar	O
concentrations	O
of	O
the	O
ligand	O
,	O
starting	O
at	O
30	O
min	O
after	O
stimulation	O
.	O


The	O
antagonists	O
,	O
however	O
,	O
had	O
no	O
effect	O
on	O
phorbol	O
ester-induced	O
up-regulation	O
of	O
HB-EGF	B-RNA
mRNA	I-RNA
and	O
kappa	O
B	O
binding	O
activity	O
.	O


Pretreatment	O
of	O
monocytes	B-cell_type
with	O
pertussis	O
toxin	O
inhibited	O
these	O
functions	O
of	O
PAF	B-protein
,	O
whereas	O
cholera	O
toxin	O
had	O
no	O
inhibitory	O
effect	O
.	O


Several	O
criteria	O
indicated	O
that	O
the	O
defect	O
in	O
this	O
cell	O
line	O
influences	O
the	O
activity	O
of	O
an	O
isotype-specific	B-protein
transcription	I-protein
factor	I-protein
.	O


Indeed	O
,	O
transient	O
transfection	O
of	O
HLA-DRA	B-DNA
and	I-DNA
DQB	I-DNA
reporter	I-DNA
constructs	I-DNA
indicated	O
that	O
the	O
affected	O
factor	O
operates	O
via	O
cis-elements	B-DNA
located	O
between	O
-141	B-DNA
base	I-DNA
pairs	I-DNA
and	O
the	O
transcription	B-DNA
initiation	I-DNA
site	I-DNA
.	O


Substitution	O
promoters	O
were	O
then	O
generated	O
where	O
the	O
entire	O
X-box	B-DNA
,	O
or	O
only	O
the	O
X1-	B-DNA
or	I-DNA
X2-boxes	I-DNA
of	O
HLA-DRA	B-DNA
were	O
replaced	O
with	O
the	O
analogous	O
regions	O
of	O
HLA-DQB	B-DNA
.	O


These	O
studies	O
suggest	O
that	O
the	O
divergent	B-DNA
X2-box	I-DNA
of	O
the	O
class	B-DNA
II	I-DNA
major	I-DNA
histocompatibility	I-DNA
complex	I-DNA
promoters	I-DNA
plays	O
an	O
important	O
role	O
in	O
influencing	O
differential	O
expression	O
of	O
the	O
human	B-DNA
class	I-DNA
II	I-DNA
isotypes	I-DNA
.	O


The	O
ZEBRA	B-protein
protein	I-protein
has	O
a	O
unique	O
biological	O
function	O
among	O
herpesviral	B-protein
proteins	I-protein
.	O


Both	O
chimeras	O
were	O
found	O
to	O
transactivate	O
model	O
and	O
native	O
promoters	O
at	O
equivalent	O
or	O
better	O
levels	O
than	O
ZEBRA	B-protein
itself	O
.	O


These	O
studies	O
suggest	O
that	O
the	O
specificities	O
of	O
some	O
of	O
the	O
known	O
biological	O
functions	O
of	O
ZEBRA	B-protein
are	O
not	O
dependent	O
upon	O
the	O
nature	O
of	O
the	O
activation	B-protein
domain	I-protein
present	I-protein
within	O
ZEBRA	B-protein
.	O


Interleukin	B-protein
4	I-protein
activates	O
a	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	B-protein
(	I-protein
Stat	I-protein
)	I-protein
protein	I-protein
which	O
interacts	O
with	O
an	O
interferon-gamma	B-DNA
activation	I-DNA
site-like	I-DNA
sequence	I-DNA
upstream	O
of	O
the	O
I	B-DNA
epsilon	I-DNA
exon	I-DNA
in	O
a	O
human	B-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O


Germ	B-RNA
line	I-RNA
C	I-RNA
transcripts	I-RNA
can	O
be	O
induced	O
by	O
IL-4	B-protein
in	O
the	O
human	B-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
BL-2	B-cell_line
.	O


This	O
factor	O
was	O
designated	O
IL-4	B-protein
NAF	I-protein
(	O
IL-4-induced	B-protein
nuclear-activating	I-protein
factors	I-protein
)	O
and	O
was	O
identified	O
as	O
a	O
tyrosine	B-protein
phosphoprotein	I-protein
,	O
which	O
translocates	O
from	O
the	O
cytosol	O
to	O
the	O
nucleus	O
upon	O
IL-4	B-protein
treatment	O
.	O


Cotransfection	O
of	O
JAK3	B-protein
with	O
IL-4	B-protein
Stat	I-protein
into	O
COS-7	B-cell_line
cells	I-cell_line
produced	O
an	O
intracellular	O
activity	O
which	O
bound	O
the	O
same	O
IFN-gamma	B-DNA
activation	I-DNA
site-like	I-DNA
sequence	I-DNA
and	O
comigrated	O
with	O
IL-4	B-protein
NAF	I-protein
in	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O


Almost	O
25	O
%	O
of	O
patients	O
with	O
T-cell	O
acute	O
lymphoblastic	O
leukemia	O
(	O
T-ALL	O
)	O
have	O
tumor-specific	O
rearrangements	O
of	O
the	O
TAL1	B-DNA
gene	I-DNA
.	O


Hence	O
,	O
it	O
has	O
been	O
proposed	O
that	O
ectopic	O
expression	O
of	O
TAL1	B-protein
promotes	O
the	O
development	O
of	O
T-ALL	O
.	O


In	O
this	O
report	O
,	O
we	O
show	O
that	O
TAL1	B-protein
is	O
expressed	O
in	O
the	O
leukemic	B-cell_type
cells	I-cell_type
of	O
most	O
patients	O
with	O
T-ALL	O
,	O
including	O
many	O
that	O
do	O
not	O
display	O
an	O
apparent	O
TAL1	B-DNA
gene	I-DNA
alteration	O
.	O


In	O
the	O
leukemic	B-cell_type
cells	I-cell_type
of	O
patients	O
without	O
detectable	O
TAL1	B-protein
rearrangements	O
,	O
TAL1	B-protein
transcription	O
occurred	O
in	O
either	O
a	O
monoallelic	O
(	O
3	O
of	O
7	O
patients	O
)	O
or	O
a	O
biallelic	O
(	O
4	O
of	O
7	O
patients	O
)	O
fashion	O
.	O


Thus	O
,	O
TAL1	B-protein
activation	O
in	O
these	O
patients	O
may	O
result	O
from	O
subtle	O
alterations	O
in	O
cis-acting	B-DNA
regulatory	I-DNA
sequences	I-DNA
(	O
affecting	O
expression	O
of	O
a	O
single	B-DNA
TAL1	I-DNA
allele	I-DNA
)	O
or	O
changes	O
in	O
trans-acting	O
factors	O
that	O
control	O
TAL1	B-protein
transcription	O
(	O
affecting	O
expression	O
of	O
both	O
TAL1	B-DNA
alleles	I-DNA
)	O
.	O


To	O
clarify	O
properties	O
of	O
the	O
blast	B-cell_type
cells	I-cell_type
in	O
M7	O
and	O
TMD	O
cases	O
,	O
we	O
examined	O
erythroid	O
markers	O
expression	O
in	O
blasts	B-cell_type
from	O
six	O
cases	O
with	O
M7	O
and	O
seven	O
cases	O
with	O
TMD	O
in	O
this	O
study	O
.	O


We	O
have	O
previously	O
found	O
a	O
high	O
expression	O
of	O
human	B-RNA
Ah	I-RNA
receptor	I-RNA
(	I-RNA
TCDD	I-RNA
receptor	I-RNA
)	I-RNA
mRNA	I-RNA
in	O
peripheral	B-cell_type
blood	I-cell_type
cells	I-cell_type
of	O
individuals	O
.	O


In	O
this	O
paper	O
,	O
the	O
expression	O
of	O
this	O
gene	O
in	O
blood	B-cell_type
cells	I-cell_type
was	O
first	O
investigated	O
in	O
fractions	O
of	O
nucleated	B-cell_type
cells	I-cell_type
,	O
revealing	O
predominant	O
expression	O
of	O
the	O
Ah	B-DNA
receptor	I-DNA
gene	I-DNA
in	O
the	O
monocyte	B-cell_type
fraction	I-cell_type
.	O


Then	O
the	O
expression	O
levels	O
of	O
AhR	B-RNA
mRNA	I-RNA
in	O
various	O
hematopoietic	B-cell_line
cell	I-cell_line
lines	I-cell_line
were	O
examined	O
together	O
with	O
those	O
of	O
Arnt	B-protein
and	O
P450IA1	B-protein
.	O


Furthermore	O
,	O
a	O
specific	O
induction	O
of	O
AhR	B-protein
during	O
monocytic	O
differentiation	O
was	O
investigated	O
in	O
HL60	B-cell_line
and	O
HEL	B-cell_line
cells	I-cell_line
.	O


Our	O
results	O
suggest	O
that	O
AhR	B-protein
may	O
play	O
an	O
important	O
role	O
in	O
the	O
function	O
of	O
monocytes	B-cell_type
and	O
also	O
in	O
the	O
eventual	O
activation	O
of	O
environmental	O
carcinogens	O
.	O


PU.1	B-protein
and	O
Spi-B	B-protein
have	O
been	O
previously	O
described	O
as	O
being	O
predominantly	O
expressed	O
coordinately	O
in	O
macrophages	B-cell_type
and	O
B	B-cell_type
cells	I-cell_type
,	O
but	O
their	O
expression	O
in	O
early	O
hematopoietic	O
stages	O
and	O
during	O
the	O
course	O
of	O
myeloid	O
differentiation	O
to	O
monocytes	B-cell_type
and	O
macrophages	B-cell_type
or	O
to	O
neutrophils	B-cell_type
has	O
not	O
been	O
extensively	O
investigated	O
.	O


Here	O
,	O
we	O
report	O
that	O
PU.1	B-RNA
mRNA	I-RNA
is	O
upregulated	O
during	O
myeloid	O
differentiation	O
of	O
human	B-cell_line
purified	I-cell_line
CD34+	I-cell_line
cells	I-cell_line
and	O
murine	B-cell_line
multipotential	I-cell_line
FDCP-mix	I-cell_line
A4	I-cell_line
cells	I-cell_line
,	O
suggesting	O
that	O
PU.1	B-protein
is	O
upregulated	O
as	O
an	O
early	O
event	O
during	O
differentiation	O
of	O
multipotential	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
.	O


In	O
contrast	O
to	O
PU.1	B-protein
,	O
significant	O
levels	O
of	O
Spi-B	B-RNA
mRNA	I-RNA
and	O
protein	O
are	O
found	O
only	O
in	O
some	O
B-cell	B-cell_line
lines	I-cell_line
and	O
spleen	O
but	O
are	O
not	O
found	O
in	O
myeloid	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
neutrophils	B-cell_type
,	O
or	O
macrophages	B-cell_type
.	O


In	O
vitro	O
translated	O
Spi-B	B-protein
protein	I-protein
can	O
bind	O
to	O
PU.1	B-DNA
binding	I-DNA
sites	I-DNA
in	O
myeloid	B-DNA
promoters	I-DNA
and	O
transactivate	O
these	O
promoters	B-DNA
in	O
nonmyeloid	B-cell_type
cells	I-cell_type
.	O


Therefore	O
,	O
although	O
PU.1	B-protein
and	O
Spi-B	B-protein
may	O
bind	O
to	O
similar	O
DNA	O
control	O
elements	O
and	O
have	O
redundancy	O
of	O
transactivation	O
function	O
in	O
vitro	O
,	O
the	O
lack	O
of	O
significant	O
levels	O
of	O
Spi-B	B-protein
in	O
myeloid	B-cell_type
cells	I-cell_type
makes	O
it	O
unlikely	O
that	O
Spi-B	B-protein
plays	O
a	O
significant	O
role	O
in	O
myeloid	O
lineage	O
development	O
and	O
gene	O
expression	O
.	O


Identification	O
of	O
a	O
major	O
positive	B-DNA
regulatory	I-DNA
element	I-DNA
located	O
5	O
'	O
to	O
the	O
human	B-DNA
zeta-globin	I-DNA
gene	I-DNA
.	O


When	O
transfected	O
into	O
K562	B-cell_line
cells	I-cell_line
,	O
which	O
express	O
zeta-globin	B-protein
,	O
comparable	O
amounts	O
of	O
activity	O
were	O
obtained	O
from	O
the	O
-557	B-DNA
and	I-DNA
-417	I-DNA
zeta-luciferase	I-DNA
constructs	I-DNA
and	O
the	O
alpha-luciferase	B-DNA
constructs	I-DNA
when	O
no	O
enhancers	B-DNA
or	O
the	O
alpha-globin	B-DNA
locus	I-DNA
enhancers	I-DNA
were	O
used	O
.	O


Reinsertion	O
of	O
these	O
sequences	O
into	O
zeta-luciferase	B-DNA
constructs	I-DNA
missing	O
the	O
-417	O
to	O
-207	O
region	O
showed	O
that	O
the	O
sequences	O
lack	O
classical	O
enhancer	O
activity	O
.	O


Point	O
mutation	O
of	O
a	O
CCACC	B-DNA
site	I-DNA
at	O
-240	O
had	O
no	O
effect	O
.	O


Electrophoretic	O
mobility	O
shift	O
assays	O
indicated	O
that	O
the	O
-230	B-DNA
GATA-1	I-DNA
site	I-DNA
has	O
a	O
relatively	O
low	O
affinity	O
for	O
GATA-1	B-protein
.	O


This	O
element	O
requires	O
GATA-1	B-protein
and	O
additional	B-protein
unknown	I-protein
factors	I-protein
for	O
maximal	O
activity	O
.	O


T	B-cell_type
cells	I-cell_type
express	O
multiple	O
isotypes	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
and	O
although	O
it	O
is	O
well	O
accepted	O
that	O
PKCs	B-protein
have	O
an	O
important	O
role	O
in	O
T	O
cell	O
activation	O
,	O
little	O
is	O
known	O
about	O
the	O
function	O
of	O
individual	O
PKC	B-protein
isotypes	I-protein
.	O


The	O
ability	O
of	O
PKC-epsilon	B-protein
to	O
induce	O
transactivation	O
of	O
NF-AT-1	B-protein
and	O
AP-1	B-protein
was	O
similar	O
to	O
the	O
stimulatory	O
effect	O
of	O
a	O
constitutively	B-protein
activated	I-protein
p21ras	I-protein
.	O


Phorbol	O
esters	O
induce	O
expression	O
of	O
CD69	B-protein
whereas	O
none	O
of	O
the	O
activated	B-protein
PKC	I-protein
isotypes	I-protein
tested	O
were	O
able	O
to	O
have	O
this	O
effect	O
.	O


These	O
results	O
indicate	O
selective	O
functions	O
for	O
different	O
PKC	B-protein
isotypes	I-protein
in	O
T	B-cell_type
cells	I-cell_type
.	O


Moreover	O
,	O
the	O
data	O
comparing	O
the	O
effects	O
of	O
activated	B-protein
Ras	I-protein
and	O
PKC	B-protein
mutants	I-protein
suggest	O
that	O
PKC-alpha	B-protein
,	O
p21ras	B-protein
,	O
and	O
PKC-epsilon	B-protein
are	O
not	O
positioned	O
linearly	O
on	O
a	O
single	O
signal	O
transduction	O
pathway	O
.	O


Steroid	O
resistance	O
can	O
not	O
be	O
explained	O
by	O
pharmacokinetic	O
mechanisms	O
,	O
by	O
a	O
defect	O
in	O
the	O
binding	O
of	O
steroids	O
to	O
glucocorticoid	B-protein
receptors	I-protein
,	O
nor	O
by	O
defective	O
nuclear	O
translocation	O
of	O
this	O
receptor	O
,	O
thereby	O
suggesting	O
that	O
the	O
molecular	O
abnormality	O
lies	O
distal	O
to	O
nuclear	O
translocation	O
.	O


These	O
results	O
suggest	O
that	O
the	O
ability	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
to	O
bind	O
to	O
GRE	B-DNA
is	O
impaired	O
in	O
steroid-resistant	O
patients	O
because	O
of	O
a	O
reduced	O
number	O
of	O
receptors	B-protein
available	O
for	O
binding	O
to	O
DNA	O
.	O


Signaling	O
by	O
a	O
wide	O
variety	O
of	O
cytokines	B-protein
,	O
including	O
interferons	B-protein
,	O
interleukins	B-protein
,	O
and	O
growth	B-protein
factors	I-protein
,	O
involves	O
activation	O
of	O
JAK	B-protein
kinases	I-protein
and	O
Stat	B-protein
(	I-protein
Signal	I-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
)	I-protein
proteins	I-protein
.	O


Human	B-cell_type
eosinophils	I-cell_type
are	O
one	O
of	O
the	O
most	O
important	O
target	B-cell_type
cells	I-cell_type
for	O
IL-5	B-protein
and	O
were	O
used	O
here	O
to	O
study	O
IL-5	B-protein
signaling	O
in	O
a	O
primary	B-cell_type
human	I-cell_type
cell	I-cell_type
.	O


IL-5	B-protein
induced	O
rapid	O
and	O
transient	O
tyrosine	O
phosphorylation	O
of	O
JAK2	B-protein
.	O


Both	O
DNA-binding	B-protein
complexes	I-protein
were	O
inhibited	O
by	O
a	O
phosphotyrosine	B-protein
antibody	I-protein
(	O
4G10	B-protein
)	O
,	O
suggesting	O
that	O
tyrosine	O
phosphorylation	O
is	O
required	O
for	O
complex	O
formation	O
.	O


Infection	O
and	O
replication	O
of	O
Tat-	O
human	O
immunodeficiency	O
viruses	O
:	O
genetic	O
analyses	O
of	O
LTR	B-DNA
and	O
tat	B-protein
mutations	I-protein
in	O
primary	B-cell_type
and	I-cell_type
long-term	I-cell_type
human	I-cell_type
lymphoid	I-cell_type
cells	I-cell_type
.	O


Mutations	O
in	O
the	O
tat	B-DNA
gene	I-DNA
have	O
been	O
shown	O
to	O
block	O
HIV	O
replication	O
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O


It	O
is	O
possible	O
that	O
Tat	B-protein
is	O
also	O
needed	O
for	O
other	O
functions	O
during	O
HIV	O
replication	O
.	O


Large	O
amounts	O
of	O
viral	B-RNA
RNA	I-RNA
and	O
particles	O
were	O
synthesized	O
in	O
infections	O
established	O
using	O
the	O
tat	B-protein
mutants	I-protein
that	O
contain	O
modified	B-DNA
LTRs	I-DNA
.	O


In	O
addition	O
,	O
HLA-DRA	B-DNA
gene	I-DNA
expression	O
is	O
inducible	O
in	O
a	O
variety	O
of	O
cell	O
types	O
by	O
interferon-gamma	B-protein
(	O
IFN-gamma	B-protein
)	O
.	O


Coexpression	O
of	O
HMG	B-protein
I/Y	I-protein
and	O
Oct-2	B-protein
in	O
cell	B-cell_line
lines	I-cell_line
lacking	O
Oct-2	B-protein
results	O
in	O
high	O
levels	O
of	O
HLA-DRA	B-DNA
gene	I-DNA
expression	O
,	O
and	O
in	O
vitro	O
DNA-binding	O
studies	O
reveal	O
that	O
HMG	O
I/Y	B-protein
stimulates	O
Oct-2A	B-protein
binding	O
to	O
the	O
HLA-DRA	B-DNA
promoter	I-DNA
.	O


By	O
contrast	O
,	O
Oct-2A	B-protein
is	O
not	O
involved	O
in	O
the	O
IFN-gamma	B-protein
induction	O
of	O
the	O
HLA-DRA	B-DNA
gene	I-DNA
in	O
HeLa	B-cell_line
cells	I-cell_line
,	O
but	O
antisense	B-DNA
HMG	I-DNA
I/Y	I-DNA
dramatically	O
decreases	O
the	O
level	O
of	O
induction	O
.	O


Epstein-Barr	B-cell_type
virus	I-cell_type
(	I-cell_type
EBV	I-cell_type
)	I-cell_type
-infected	I-cell_type
cells	I-cell_type
may	O
sustain	O
three	O
distinct	O
forms	O
of	O
virus	O
latency	O
.	O


We	O
have	O
studied	O
the	O
expression	O
of	O
EBV	B-protein
proteins	I-protein
in	O
17	O
cases	O
of	O
EBV-positive	O
endemic	O
BL	O
by	O
immunohistology	O
.	O


Expression	O
of	O
LMP1	B-protein
was	O
seen	O
in	O
variable	O
proportions	O
of	O
tumor	B-cell_type
cells	I-cell_type
in	O
two	O
cases	O
and	O
EBNA2	B-protein
was	O
detected	O
in	O
some	O
tumor	B-cell_type
cells	I-cell_type
in	O
three	O
other	O
cases	O
.	O


The	O
activation	O
of	O
the	O
Jak	B-protein
-STAT	B-protein
1	I-protein
signaling	O
pathway	O
by	O
IL-5	B-protein
in	O
eosinophils	B-cell_type
.	O


Eosinophils	B-cell_type
were	O
purified	O
from	O
peripheral	O
blood	O
by	O
discontinuous	O
Percoll	O
gradients	O
and	O
stimulated	O
with	O
IL-5	B-protein
.	O


The	O
involvement	O
of	O
Jak	B-protein
2	I-protein
was	O
investigated	O
by	O
immunoprecipitation	O
followed	O
by	O
immunoblotting	O
for	O
tyrosine	O
phosphorylation	O
.	O


Further	O
,	O
the	O
immunoprecipitated	B-protein
Jak	I-protein
2	I-protein
obtained	O
from	O
IL-5-stimulated	B-cell_line
cells	I-cell_line
underwent	O
autophosphorylation	O
.	O


STAT-1	B-protein
was	O
tyrosine	O
phosphorylated	O
within	O
15	O
min	O
of	O
IL-5	B-protein
stimulation	O
.	O


IL-5	B-protein
induced	O
two	O
proteins	O
that	O
bound	O
to	O
the	O
gamma-activating	B-DNA
sequence	I-DNA
.	O


Thus	O
,	O
we	O
demonstrated	O
that	O
IL-5	B-protein
activated	O
the	O
Jak	B-protein
2	I-protein
-STAT	B-protein
1	I-protein
signaling	O
pathway	O
in	O
eosinophils	B-cell_type
.	O


Whereas	O
PHA	B-protein
-induced	O
proliferation	O
of	O
PBMCs	B-cell_type
derived	O
from	O
patients	O
with	O
breast	O
cancer	O
preoperatively	O
was	O
significantly	O
decreased	O
when	O
compared	O
with	O
data	O
obtained	O
in	O
healthy	O
control	O
individuals	O
(	O
P	O
<	O
0.001	O
)	O
,	O
the	O
degree	O
of	O
the	O
defect	O
in	O
PHA	B-protein
-induced	O
proliferation	O
of	O
PBMCs	B-cell_type
depended	O
upon	O
the	O
tumour	O
burden	O
as	O
manifested	O
by	O
tumour	O
size	O
and	O
axillary	O
lymph	O
node	O
involvement	O
(	O
P	O
<	O
0.003	O
in	O
each	O
case	O
)	O
.	O


After	O
an	O
additional	O
6	O
months	O
(	O
i.e.	O
12	O
months	O
after	O
surgery	O
)	O
,	O
PHA	B-protein
-induced	O
proliferation	O
of	O
PBMCs	B-cell_type
was	O
similar	O
in	O
patients	O
after	O
adjuvant	O
chemotherapy	O
with	O
CMF	O
and	O
in	O
those	O
receiving	O
continued	O
adjuvant	O
tamoxifen	O
treatment	O
(	O
P	O
>	O
0.1	O
)	O
,	O
but	O
in	O
all	O
patients	O
still	O
significantly	O
decreased	O
as	O
compared	O
with	O
healthy	O
controls	O
(	O
P	O
<	O
0.001	O
)	O
.	O


In	O
contrast	O
,	O
out	O
of	O
59	O
patients	O
whose	O
PBMCs	B-cell_type
showed	O
an	O
increase	O
in	O
their	O
PHA	B-protein
-induced	O
proliferation	O
within	O
the	O
first	O
12	O
months	O
after	O
surgery	O
,	O
only	O
one	O
(	O
2	O
%	O
)	O
presented	O
with	O
disease	O
progression	O
.	O


Mutations	O
in	O
this	O
DNA-binding	B-DNA
site	I-DNA
abolished	O
binding	O
of	O
a	O
nuclear	B-protein
factor	I-protein
in	O
human	O
B	O
cell	O
nuclear	O
extract	O
and	O
decreased	O
the	O
activity	O
of	O
the	O
DR	B-DNA
alpha	I-DNA
promoter	I-DNA
to	O
a	O
basal	O
level	O
.	O


The	O
nuclear	O
factor	O
binds	O
to	O
the	O
DR	B-DNA
alpha	I-DNA
and	I-DNA
DP	I-DNA
alpha	I-DNA
element	I-DNA
but	O
not	O
to	O
the	O
element	O
in	O
the	O
DQ	B-DNA
alpha	I-DNA
gene	I-DNA
.	O


It	O
was	O
identified	O
as	O
NF-E1	B-protein
(	O
YY1	B-protein
)	O
.	O


Core	B-protein
binding	I-protein
factor	I-protein
(	O
CBF	B-protein
)	O
,	O
also	O
known	O
as	O
polyomavirus	B-protein
enhancer-binding	I-protein
protein	I-protein
2	I-protein
and	O
SL3	B-protein
enhancer	I-protein
factor	I-protein
1	I-protein
,	O
is	O
a	O
mammalian	B-protein
transcription	I-protein
factor	I-protein
that	O
binds	O
to	O
an	O
element	O
termed	O
the	O
core	O
within	O
the	O
enhancers	B-DNA
of	O
the	O
murine	O
leukemia	O
virus	O
family	O
of	O
retroviruses	O
.	O


The	O
core	B-DNA
elements	I-DNA
of	O
the	O
SL3	O
virus	O
are	O
important	O
genetic	O
determinants	O
of	O
the	O
ability	O
of	O
this	O
virus	O
to	O
induce	O
T-cell	O
lymphomas	O
and	O
the	O
transcriptional	O
activity	O
of	O
the	O
viral	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O


One	O
of	O
the	O
genes	O
that	O
encodes	O
a	O
CBF	B-protein
alpha	I-protein
subunit	I-protein
is	O
AML1	B-protein
,	O
also	O
called	O
Cbf	B-protein
alpha	I-protein
2	I-protein
.	O


Three	O
different	O
isoforms	O
of	O
CBF	B-protein
beta	I-protein
were	O
also	O
tested	O
for	O
transcriptional	O
activity	O
on	O
the	O
SL3	B-DNA
enhancer	I-DNA
.	O


These	O
results	O
indicated	O
that	O
at	O
least	O
in	O
certain	O
cell	O
types	O
,	O
the	O
maximum	O
activity	O
of	O
CBF	B-protein
required	O
both	O
subunits	O
.	O


This	O
difference	O
strongly	O
affects	O
transcription	O
in	O
T	O
cells	O
and	O
leukemogenicity	O
of	O
SL3	B-DNA
.	O


However	O
,	O
no	O
combination	O
of	O
CBF	B-protein
alpha	I-protein
and	O
CBF	B-protein
beta	I-protein
subunits	O
that	O
we	O
tested	O
was	O
able	O
to	O
distinguish	O
the	O
1-bp	O
difference	O
in	O
transcription	O
assays	O
.	O


Interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-10	I-protein
inhibits	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF	B-protein
kappa	I-protein
B	I-protein
)	O
activation	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O


Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
,	O
we	O
now	O
show	O
that	O
,	O
in	O
monocytes	O
stimulated	O
with	O
LPS	O
or	O
TNF	B-protein
alpha	I-protein
,	O
IL-10	B-protein
inhibits	O
nuclear	O
stimulation	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF	B-protein
kappa	I-protein
B	I-protein
)	O
,	O
a	O
transcription	B-protein
factor	I-protein
involved	O
in	O
the	O
expression	O
of	O
inflammatory	B-DNA
cytokine	I-DNA
genes	I-DNA
.	O
Several	O
other	O
transcription	B-protein
factors	I-protein
including	O
NF-	O
IL-6	B-protein
,	O
AP-1	B-protein
,	O
AP-2	B-protein
,	O
GR	B-protein
,	O
CREB	B-protein
,	O
Oct-1	B-protein
,	O
and	O
Sp-1	B-protein
are	O
not	O
affected	O
by	O
IL-10	B-protein
.	O


This	O
selective	O
inhibition	O
by	O
IL-10	B-protein
of	O
NF	B-protein
kappa	I-protein
B	I-protein
activation	O
occurs	O
rapidly	O
and	O
in	O
a	O
dose-dependent	O
manner	O
and	O
correlates	O
well	O
with	O
IL-10	B-protein
's	O
cytokine	B-protein
synthesis	O
inhibitory	O
activity	O
in	O
terms	O
of	O
both	O
kinetics	O
and	O
dose	O
responsiveness	O
.	O


Furthermore	O
,	O
compounds	O
such	O
as	O
tosylphenylalanyl	O
chloromethyl	O
ketone	O
and	O
pyrrolidinedithiocarbamate	O
that	O
are	O
known	O
to	O
selectively	O
inhibit	O
NF	B-protein
kappa	I-protein
B	I-protein
activation	O
block	O
cytokine	O
gene	O
transcription	O
in	O
LPS-stimulated	B-cell_line
monocytes	I-cell_line
.	O


Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
inhibition	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
activation	O
may	O
be	O
an	O
important	O
mechanism	O
for	O
IL-10	B-protein
suppression	O
of	O
cytokine	O
gene	O
transcription	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O


NF-kappa	B-protein
B	I-protein
,	O
a	O
transcription	B-protein
factor	I-protein
controlling	O
the	O
expression	O
of	O
genes	B-DNA
involved	O
in	O
cell	O
activation	O
and	O
growth	O
control	O
,	O
has	O
been	O
shown	O
to	O
be	O
activated	O
by	O
LMP-1	B-protein
.	O


A	O
DNA	B-DNA
response	I-DNA
element	I-DNA
(	O
TR2RE-SV40	B-DNA
)	O
for	O
the	O
TR2	B-protein
orphan	I-protein
receptor	I-protein
,	O
a	O
member	O
of	O
the	O
steroid-thyroid	B-protein
hormone	I-protein
receptor	I-protein
superfamily	I-protein
,	O
has	O
been	O
identified	O
in	O
the	O
simian	B-DNA
virus	I-DNA
40	I-DNA
(	I-DNA
SV40	I-DNA
)	I-DNA
+55	I-DNA
region	I-DNA
(	O
nucleotide	B-DNA
numbers	I-DNA
368-389	I-DNA
,	O
5'-GTTAAGGTTCGTAGGTCATGGA-3	O
'	O
)	O
.	O


Electrophoretic	O
mobility	O
shift	O
assay	O
,	O
using	O
in	O
vitro	O
translated	O
TR2	B-protein
orphan	I-protein
receptor	I-protein
with	O
a	O
molecular	O
mass	O
of	O
67	B-protein
kilodaltons	I-protein
,	O
showed	O
a	O
specific	O
binding	O
with	O
high	O
affinity	O
(	O
dissociation	O
constant	O
=	O
9	O
nM	O
)	O
for	O
this	O
DNA	O
sequence	O
.	O


In	O
addition	O
,	O
this	O
TR2RE-SV40	B-DNA
can	O
function	O
as	O
a	O
repressor	O
to	O
suppress	O
the	O
transcriptional	O
activities	O
of	O
both	O
SV40	B-DNA
early	I-DNA
and	I-DNA
late	I-DNA
promoters	I-DNA
.	O


We	O
have	O
analyzed	O
CBF	B-RNA
beta-MYH11	I-RNA
fusion	I-RNA
transcripts	I-RNA
by	O
RT-PCR	O
in	O
myelomonocytic	O
leukemias	O
,	O
with	O
or	O
without	O
eosinophilia	O
,	O
to	O
determine	O
whether	O
their	O
presence	O
correlates	O
with	O
morphology	O
.	O


Fifty-three	O
cases	O
(	O
11	O
AML	O
M4Eo	O
;	O
1	O
AML	O
M4	O
with	O
atypical	B-cell_type
abnormal	I-cell_type
eosinophils	I-cell_type
(	O
AML	O
M4	O
``	O
Eo	O
''	O
)	O
;	O
29	O
AML	O
M4	O
;	O
8	O
AML	O
M5	O
;	O
3	O
CMML	O
;	O
and	O
1	O
AML	O
M2	O
with	O
eosinophilia	O
)	O
were	O
analyzed	O
.	O


Three	O
of	O
29	O
(	O
10	O
%	O
)	O
AML	O
M4	O
without	O
abnormal	B-cell_type
eosinophils	I-cell_type
were	O
CBF	B-DNA
beta	I-DNA
-MYH11	B-DNA
positive	O
,	O
1	O
of	O
which	O
did	O
not	O
show	O
any	O
apparent	O
chromosome	B-DNA
16	I-DNA
abnormalities	O
by	O
classical	O
metaphase	O
analysis	O
(	O
2	O
not	O
tested	O
)	O
.	O


Both	O
cases	O
tested	O
also	O
showed	O
MYH11	B-DNA
genomic	O
rearrangement	O
.	O


In	O
HeLa	B-cell_line
cells	I-cell_line
stably	O
transfected	O
with	O
the	O
HIV-1	B-DNA
tat	I-DNA
gene	I-DNA
(	O
HeLa-tat	B-cell_line
cells	I-cell_line
)	O
,	O
expression	O
of	O
the	O
Tat	B-protein
protein	I-protein
enhanced	O
both	O
TNF	B-protein
-induced	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
TNF	B-protein
-mediated	O
cytotoxicity	O
.	O


TNF	B-protein
-mediated	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
cytotoxicity	O
involves	O
the	O
intracellular	O
formation	O
of	O
reactive	O
oxygen	O
intermediates	O
.	O


Thus	O
,	O
Mn-SOD	B-protein
RNA	O
protein	O
levels	O
and	O
activity	O
were	O
markedly	O
reduced	O
in	O
the	O
presence	O
of	O
Tat	B-protein
.	O


Thus	O
,	O
our	O
experiments	O
demonstrate	O
that	O
the	O
C-terminal	B-protein
region	I-protein
of	O
HIV-1	B-protein
Tat	I-protein
is	O
required	O
to	O
suppress	O
Mn-SOD	B-protein
expression	O
and	O
to	O
induce	O
pro-oxidative	O
conditions	O
reflected	O
by	O
a	O
drop	O
in	O
reduced	O
glutathione	O
(	O
GSH	B-protein
)	O
and	O
the	O
GSH	O
:	O
oxidized	O
GSH	O
(	O
GSSG	O
)	O
ratio	O
.	O


Epstein-Barr	B-protein
virus	I-protein
nuclear	I-protein
protein	I-protein
2	I-protein
transactivation	O
of	O
the	O
latent	B-DNA
membrane	I-DNA
protein	I-DNA
1	I-DNA
promoter	I-DNA
is	O
mediated	O
by	O
J	B-protein
kappa	I-protein
and	O
PU.1	B-protein
.	O


EBNA-2	B-protein
is	O
known	O
to	O
interact	O
with	O
the	O
cellular	B-protein
DNA-binding	I-protein
protein	I-protein
J	B-protein
kappa	I-protein
and	O
is	O
recruited	O
to	O
promoters	B-DNA
containing	O
the	O
GTGGGAA	O
J	B-DNA
kappa	I-DNA
recognition	I-DNA
sequence	I-DNA
.	O


The	O
previously	O
characterized	O
factors	O
J	B-protein
kappa	I-protein
,	O
PU.1	B-protein
,	O
and	O
AML1	B-protein
bind	O
to	O
the	O
LMP-1	B-DNA
E2RE	I-DNA
,	O
along	O
with	O
six	O
other	O
unidentified	O
factors	O
(	O
LBF2	B-protein
to	O
LBF7	B-protein
)	O
.	O


LBF4	B-protein
has	O
a	O
molecular	O
mass	O
of	O
105	O
kDa	O
and	O
is	O
probably	O
unrelated	O
to	O
PU.1	B-protein
.	O


Mutations	O
of	O
the	O
AML1-	B-DNA
or	I-DNA
LBF4-binding	I-DNA
sites	I-DNA
had	O
no	O
effect	O
on	O
EBNA-2	B-protein
transactivation	O
,	O
whereas	O
mutation	O
of	O
the	O
PU.1-binding	B-DNA
site	I-DNA
completely	O
eliminated	O
EBNA-2	B-protein
responses	O
.	O


LBF3	B-protein
,	O
LBF5	B-protein
,	O
LBF6	B-protein
,	O
or	O
LBF7	B-protein
may	O
also	O
be	O
involved	O
,	O
since	O
their	O
binding	O
sites	O
also	O
contribute	O
to	O
EBNA-2	B-protein
responsiveness	O
.	O


We	O
hypothesized	O
that	O
lymphocyte	B-protein
GCII	I-protein
is	O
altered	O
in	O
adolescent	O
MDD	O
and	O
could	O
serve	O
as	O
a	O
marker	O
for	O
response	O
to	O
SRIs	O
.	O


Only	O
SRI	O
responders	O
showed	O
GCII	B-protein
sites/cell	O
upregulated	O
after	O
6	O
weeks	O
of	O
treatment	O
(	O
t	O
=	O
2.1	O
,	O
df	O
=	O
10	O
;	O
p	O
<	O
.05	O
)	O
.	O


Here	O
,	O
we	O
demonstrate	O
that	O
the	O
kappa	B-protein
3	I-protein
binding	I-protein
factor	I-protein
contains	O
NFATp	B-protein
,	O
a	O
cyclosporin-sensitive	B-protein
DNA-binding	I-protein
protein	I-protein
required	O
for	O
interleukin-2	B-DNA
gene	I-DNA
transcription	O
.	O


The	O
involvement	O
of	O
NFATp	B-protein
in	O
transcriptional	O
activation	O
of	O
both	O
the	O
interleukin-2	B-protein
and	O
TNF	B-DNA
alpha	I-DNA
genes	I-DNA
suggests	O
that	O
this	O
factor	O
plays	O
an	O
important	O
role	O
in	O
the	O
coordinate	O
induction	O
of	O
multiple	O
cytokine	B-DNA
genes	I-DNA
,	O
starting	O
at	O
the	O
earliest	O
stages	O
of	O
T	O
cell	O
activation	O
.	O


Regulation	O
and	O
specificity	O
of	O
MNDA	B-protein
expression	O
in	O
monocytes	B-cell_type
,	O
macrophages	B-cell_type
,	O
and	O
leukemia/B	B-cell_line
lymphoma	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O


The	O
specificity	O
of	O
MNDA	B-protein
expression	O
for	O
cells	O
in	O
the	O
granulocyte-macrophage	O
lineage	O
was	O
reexamined	O
in	O
cell	B-cell_line
lines	I-cell_line
established	O
from	O
patients	O
with	O
Philadelphia	O
chromosome-positive	O
chronic	O
myeloid	O
leukemia	O
.	O


Cell	O
lines	O
that	O
expressed	O
MNDA	B-protein
exhibited	O
myeloid	O
cell	O
features	O
and	O
granulocyte	O
or	O
monocyte	O
differentiation	O
could	O
be	O
induced	O
in	O
vitro	O
,	O
while	O
cell	O
lines	O
exhibiting	O
properties	O
of	O
very	O
early	O
stage	O
cells	O
or	O
multipotential	B-cell_type
cells	I-cell_type
did	O
not	O
express	O
MNDA	B-protein
.	O


Changes	O
in	O
MNDA	B-protein
expression	O
occurred	O
slowly	O
(	O
hours	O
to	O
days	O
)	O
,	O
suggesting	O
that	O
MNDA	B-protein
could	O
mediate	O
changes	O
realized	O
over	O
a	O
long	O
period	O
.	O


The	O
results	O
also	O
reveal	O
a	O
discordance	O
in	O
certain	O
MNDA	B-cell_line
positive	I-cell_line
cells	I-cell_line
between	O
steady-state	O
levels	O
or	O
changes	O
in	O
levels	O
of	O
protein	O
and	O
mRNA	B-RNA
indicating	O
that	O
the	O
regulation	O
of	O
MNDA	B-protein
expression	O
occurs	O
at	O
more	O
than	O
one	O
point	O
.	O


Changes	O
in	O
MNDA	B-protein
expression	O
are	O
consistent	O
with	O
a	O
role	O
in	O
opposing	O
macrophage	O
differentiation	O
and	O
activation	O
of	O
monocytes	B-cell_type
/macrophages	B-cell_type
.	O


Trans-activation	O
of	O
the	O
TP1	B-DNA
promoter	I-DNA
and	O
of	O
the	O
BamHI	B-DNA
C	I-DNA
promoter	I-DNA
has	O
already	O
been	O
investigated	O
in	O
detail	O
and	O
appears	O
to	O
be	O
mediated	O
via	O
protein-protein	O
interactions	O
and	O
not	O
by	O
direct	O
binding	O
of	O
EBNA-2	B-protein
type	I-protein
A	I-protein
(	O
of	O
EBV	O
type	O
1	O
)	O
to	O
the	O
DNA	O
.	O


Various	O
reports	O
have	O
delineated	O
the	O
cis-acting	B-DNA
elements	I-DNA
of	O
the	O
LMP	B-DNA
promoter	I-DNA
through	O
which	O
EBNA-2	B-protein
mediates	O
trans-activation	O
.	O


We	O
determined	O
that	O
the	O
protein-binding	B-DNA
region	I-DNA
on	O
the	O
LMP	B-DNA
promoter	I-DNA
was	O
within	O
a	O
42	B-DNA
bp	I-DNA
fragment	I-DNA
encompassing	O
nucleotides	O
-135	O
to	O
-176	O
relative	O
to	O
the	O
LMP	B-DNA
transcriptional	I-DNA
start	I-DNA
site	I-DNA
.	O


No	O
significant	O
differences	O
between	O
EBNA-2	B-protein
-positive	O
and	O
EBNA-2	B-protein
-negative	O
nuclear	O
extracts	O
could	O
be	O
seen	O
in	O
the	O
gel	O
retardation	O
assay	O
under	O
conditions	O
that	O
clearly	O
showed	O
binding	O
of	O
EBNA-2A	B-protein
to	O
the	O
TP1	B-DNA
promoter	I-DNA
.	O


However	O
,	O
analysis	O
of	O
sucrose	O
gradient	O
fractions	O
in	O
the	O
gel	O
retardation	O
assay	O
provided	O
evidence	O
that	O
the	O
LMP	B-protein
promoter-binding	I-protein
proteins	I-protein
form	O
a	O
complex	O
of	O
higher	O
M	O
(	O
r	O
)	O
in	O
EBNA-2-positive	B-cell_type
cell	I-cell_type
extracts	O
.	O


Simultaneous	O
activation	O
of	O
Ig	B-protein
and	O
Oct-2	B-protein
synthesis	O
and	O
reduction	O
of	O
surface	O
MHC	B-protein
class	I-protein
II	I-protein
expression	O
by	O
IL-6	B-protein
.	O


The	O
IL-6-induced	B-cell_line
cells	I-cell_line
resemble	O
plasma	B-cell_type
cells	I-cell_type
in	O
ultrastructure	O
and	O
in	O
reduced	O
expression	O
of	O
surface	B-protein
MHC	I-protein
class	I-protein
II	I-protein
.	O


Enhanced	O
Ig	B-protein
synthesis	O
is	O
a	O
result	O
of	O
coordinated	O
transcriptional	O
activation	O
of	O
Ig	B-DNA
genes	I-DNA
without	O
promoter	O
or	O
isotype	O
specificity	O
,	O
and	O
differential	O
accumulation	O
of	O
the	O
mRNA	B-RNA
encoding	O
the	O
secreted	O
form	O
of	O
Ig	B-protein
heavy	I-protein
chain	I-protein
.	O


The	O
human	B-DNA
interleukin-3	I-DNA
(	I-DNA
IL-3	I-DNA
)	I-DNA
gene	I-DNA
is	O
expressed	O
almost	O
exclusively	O
in	O
activated	O
T	B-cell_type
cells	I-cell_type
.	O


To	O
define	O
the	O
regions	O
of	O
the	O
gene	O
required	O
for	O
transcription	O
activation	O
,	O
we	O
generated	O
a	O
series	O
of	O
reporter	O
constructs	O
containing	O
different	O
regions	O
of	O
the	O
IL-3	B-DNA
gene	I-DNA
5	I-DNA
'	I-DNA
and	I-DNA
3	I-DNA
'	I-DNA
flanking	I-DNA
sequences	I-DNA
.	O


The	O
transcription	B-protein
factor	I-protein
AP-1	B-protein
could	O
bind	O
to	O
this	O
positive	O
activator	O
region	O
of	O
the	O
promoter	O
.	O


We	O
also	O
examined	O
the	O
function	O
of	O
the	O
IL-3	B-DNA
CK-1/CK-2	I-DNA
elements	I-DNA
that	O
are	O
present	O
in	O
many	O
cytokine	B-DNA
genes	I-DNA
and	O
found	O
that	O
they	O
acted	O
as	O
a	O
repressor	O
of	O
basal	O
level	O
expression	O
when	O
cloned	O
upstream	O
of	O
a	O
heterologous	B-DNA
promoter	I-DNA
but	O
were	O
also	O
inducible	O
by	O
PMA	O
/PHA	B-protein
.	O


Furthermore	O
,	O
transcripts	O
of	O
PEBP2	B-protein
alpha	I-protein
A	I-protein
and	O
mouse	B-protein
AML1/PEBP2	I-protein
alpha	I-protein
B	I-protein
were	O
detected	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
in	O
the	O
thymuses	O
from	O
day	O
16	O
embryos	O
and	O
newborns	O
,	O
as	O
well	O
as	O
4-week-old	O
adult	O
mice	O
,	O
by	O
in	O
situ	O
hybridization	O
.	O


The	O
implication	O
of	O
mouse	O
AML1/PEBP2	B-protein
alpha	I-protein
B	I-protein
expression	O
in	O
hematopoietic	B-cell_type
cells	I-cell_type
other	O
than	O
those	O
of	O
T-cell	B-cell_type
lineage	I-cell_type
is	O
discussed	O
in	O
relation	O
to	O
myeloid	O
leukemogenesis	O
.	O


Effects	O
of	O
glucocorticoids	O
on	O
transcription	O
factor	O
activation	O
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O


TNF-alpha	O
,	O
IL-1	O
beta	O
and	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
treatment	O
increased	O
AP-1	B-protein
and	O
NF	O
kappa	O
B	O
DNA	O
binding	O
by	O
up	O
to	O
200	O
%	O
but	O
decreased	O
CREB	B-protein
binding	O
(	O
38	O
%	O
)	O
over	O
a	O
60-min	O
time	O
course	O
.	O


Dexamethasone	O
produced	O
a	O
rapid	O
and	O
sustained	O
increase	O
in	O
glucocorticoid	B-DNA
response	I-DNA
element	I-DNA
binding	O
and	O
a	O
concomitant	O
40-50	O
%	O
decrease	O
in	O
AP-1	O
,	O
NF	O
kappa	O
B	O
,	O
and	O
CREB	O
DNA	O
binding	O
that	O
was	O
blocked	O
by	O
combined	O
dexamethasone	O
and	O
cytokine	B-protein
or	O
PMA	O
treatment	O
.	O


This	O
suggests	O
that	O
in	O
these	O
cells	O
GR	B-protein
within	O
the	O
nucleus	O
interacts	O
with	O
cytokine-stimulated	B-protein
transcription	I-protein
factors	I-protein
by	O
the	O
process	O
of	O
cross	O
coupling	O
.	O


Stimulation	O
of	O
human	B-cell_line
CD4+	I-cell_line
T-cell	I-cell_line
clones	I-cell_line
through	O
the	O
T-cell	B-protein
receptor	I-protein
(	O
TcR	B-protein
)	O
by	O
high	O
doses	O
of	O
specific	O
peptide	O
results	O
in	O
the	O
induction	O
of	O
a	O
long-lived	O
state	O
of	O
nonresponsiveness	O
that	O
has	O
been	O
called	O
anergy	O
.	O


The	O
amount	O
of	O
TcR	B-protein
at	O
the	O
cell	O
surface	O
is	O
downmodulated	O
,	O
whereas	O
the	O
CD2	B-protein
and	I-protein
CD25	I-protein
receptors	I-protein
are	O
increased	O
.	O


The	O
pattern	O
of	O
binding	O
activity	O
in	O
restimulated	O
T	B-cell_type
cells	I-cell_type
is	O
consistent	O
with	O
the	O
pattern	O
that	O
has	O
previously	O
been	O
shown	O
to	O
regulate	O
T-cell-specific	O
expression	O
of	O
the	O
IL-2	B-protein
and	O
the	O
beta	O
chain	O
of	O
the	O
TcR	B-DNA
genes	I-DNA
.	O


The	O
measured	O
binding	O
to	O
a	O
TCF-1	B-DNA
site	I-DNA
is	O
the	O
same	O
in	O
the	O
nuclei	O
of	O
resting	B-cell_type
,	I-cell_type
activated	I-cell_type
,	I-cell_type
and	I-cell_type
anergized	I-cell_type
cells	I-cell_type
.	O


The	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
peripheral	B-cell_type
human	I-cell_type
lymphocytes	I-cell_type
is	O
elevated	O
by	O
a	O
zinc	O
containing	O
trace	O
element	O
preparation	O
.	O


This	O
enhancement	O
by	O
BDP	O
was	O
found	O
either	O
for	O
constitutive	O
expression	O
of	O
gcRs	B-protein
or	O
in	O
experiments	O
when	O
the	O
lymphocytes	B-cell_type
were	O
stimulated	O
by	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-6	I-protein
.	O


The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
mutations	O
in	O
the	O
glucocorticoid	B-protein
receptor	I-protein
could	O
account	O
for	O
the	O
increasing	O
unresponsiveness	O
of	O
patients	O
with	O
chronic	O
lymphatic	O
leukemia	O
(	O
CLL	O
)	O
to	O
combination	O
chemotherapy	O
.	O


This	O
conclusion	O
is	O
discussed	O
in	O
relation	O
to	O
the	O
mechanism	O
of	O
corticoid	O
resistance	O
in	O
mouse	B-cell_line
and	I-cell_line
human	I-cell_line
lymphoma	I-cell_line
cells	I-cell_line
in	O
culture	O
.	O


The	O
binding	O
activity	O
is	O
greatly	O
inducible	O
in	O
pre-B	B-cell_type
cells	I-cell_type
by	O
bacterial	O
lipopolysaccharide	O
and	O
interleukin-1	B-protein
but	O
specific	O
complexes	O
are	O
found	O
at	O
all	O
stages	O
of	O
B	O
cell	O
development	O
tested	O
.	O


The	O
footprinted	B-DNA
binding	I-DNA
site	I-DNA
is	O
homologous	O
to	O
the	O
consensus	B-DNA
AP1	I-DNA
motif	I-DNA
.	O


The	O
protein	O
components	O
of	O
this	O
complex	O
are	O
specifically	O
competed	O
by	O
an	O
AP1	B-DNA
consensus	I-DNA
motif	I-DNA
and	O
were	O
shown	O
by	O
supershift	O
to	O
include	O
c-Jun	B-protein
and	O
c-Fos	B-protein
,	O
suggesting	O
that	O
this	O
binding	B-DNA
site	I-DNA
is	O
an	O
AP1	B-DNA
motif	I-DNA
and	O
that	O
the	O
Jun	B-protein
and	I-protein
Fos	I-protein
families	I-protein
of	O
transcription	B-protein
factors	I-protein
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
the	O
kappa	B-DNA
light	I-DNA
chain	I-DNA
gene	I-DNA
.	O


Methylation	O
studies	O
indicated	O
that	O
the	O
tal-15	B-DNA
'	I-DNA
GC-rich	I-DNA
region	I-DNA
behaves	O
like	O
a	O
CpG	B-DNA
island	I-DNA
,	O
hypomethylated	O
in	O
normal	B-cell_type
cells	I-cell_type
,	O
and	O
methylated	O
de	O
novo	O
on	O
transcriptionally	B-DNA
inactive	I-DNA
alleles	I-DNA
in	O
established	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O


These	O
results	O
suggest	O
that	O
distinct	O
regulatory	B-DNA
elements	I-DNA
are	O
associated	O
with	O
the	O
use	O
of	O
the	O
different	O
tal-1	B-DNA
promoters	I-DNA
.	O


Peripheral	B-cell_type
blood	I-cell_type
resting	I-cell_type
cells	I-cell_type
did	O
not	O
express	O
cdc2	B-RNA
mRNA	I-RNA
,	O
but	O
it	O
was	O
induced	O
in	O
T-lymphocytes	B-cell_type
when	O
the	O
cells	O
reentered	O
the	O
cell	O
cycle	O
in	O
response	O
to	O
specific	O
mitogens	O
.	O


Association	O
of	O
alterations	O
in	O
NF-kappa	B-protein
B	I-protein
moieties	I-protein
with	O
HIV	O
type	O
1	O
proviral	O
latency	O
in	O
certain	O
monocytic	B-cell_type
cells	I-cell_type
.	O


Human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
replication	O
is	O
controlled	O
by	O
a	O
complex	O
array	O
of	O
virally	B-protein
encoded	I-protein
and	I-protein
cellular	I-protein
proteins	I-protein
.	O


A	O
predominance	O
of	O
p50	B-protein
NF-kappa	I-protein
B	I-protein
moieties	I-protein
and	O
possibly	O
p50	B-protein
homodimers	I-protein
or	O
closely	O
related	O
species	O
,	O
rather	O
than	O
the	O
p50-p56	B-protein
heterodimer	I-protein
of	O
NF-kappa	B-protein
B	I-protein
that	O
is	O
the	O
predominant	O
NF-kappa	B-protein
B	I-protein
species	O
in	O
most	O
T	B-cell_type
lymphocytic	I-cell_type
and	I-cell_type
monocytic	I-cell_type
cells	I-cell_type
,	O
is	O
demonstrated	O
in	O
the	O
nuclei	O
of	O
U1	B-cell_line
cells	I-cell_line
.	O


[	O
Regulation	O
of	O
transcription	O
of	O
the	O
interleukin-2	B-DNA
gene	I-DNA
in	O
B-lymphocytes	B-cell_type
]	O


Since	O
most	O
B	B-cell_line
cell	I-cell_line
clones	I-cell_line
immortalized	O
with	O
EBV	O
virus	O
can	O
be	O
induced	O
to	O
produce	O
interleukin-2	B-protein
,	O
a	O
typical	O
T	B-protein
cell	I-protein
cytokine	I-protein
,	O
we	O
studied	O
the	O
role	O
of	O
different	O
elements	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
in	O
such	O
clones	O
by	O
transfection	O
.	O


The	O
mechanisms	O
regulating	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
persistence	O
in	O
human	O
monocytes	B-cell_type
/macrophages	B-cell_type
are	O
partially	O
understood	O
.	O


To	O
further	O
delineate	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
HIV-infected	O
monocytes	B-cell_type
and	O
macrophages	B-cell_type
,	O
we	O
have	O
focused	O
on	O
the	O
regulation	O
of	O
the	O
I	O
kappa	O
B	O
molecules	O
.	O


This	O
parallels	O
the	O
increased	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
synthesis	O
secondary	O
to	O
increased	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
gene	O
transcription	O
,	O
i.e.	O
,	O
increased	O
RNA	O
and	O
transcriptional	O
activity	O
of	O
its	O
promoter-enhancer	O
.	O


Furthermore	O
,	O
persistent	O
HIV	O
infection	O
of	O
monocytes	B-cell_type
and	O
macrophages	B-cell_type
provides	O
a	O
useful	O
model	O
with	O
which	O
to	O
study	O
concomitant	O
modifications	O
of	O
different	O
I	B-protein
kappa	I-protein
B	I-protein
molecules	I-protein
.	O


Induction	O
of	O
apoptosis	O
in	O
lymphocytes	B-cell_type
,	O
which	O
may	O
account	O
for	O
the	O
therapeutic	O
effects	O
of	O
glucocorticoids	O
in	O
various	O
diseases	O
including	O
leukemia	O
,	O
depends	O
on	O
the	O
glucocorticoid	B-protein
receptor	I-protein
.	O


It	O
has	O
been	O
reported	O
that	O
HIV-1	B-protein
protease	I-protein
may	O
cleave	O
the	O
NF-kappa	B-protein
B	I-protein
precursor	O
to	O
its	O
active	O
form	O
in	O
vitro	O
.	O


The	O
limited	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
by	O
HIV	B-protein
protease	I-protein
appears	O
unlikely	O
to	O
have	O
a	O
significant	O
effect	O
on	O
virus	O
expression	O
or	O
T	O
cell	O
function	O
.	O


Enhancement	O
of	O
IFNA	B-protein
synthesis	O
observed	O
upon	O
HIV-1	O
infection	O
resulted	O
in	O
significant	O
inhibition	O
of	O
HIV-1	O
replication	O
for	O
a	O
period	O
of	O
at	O
least	O
30	O
days	O
.	O


Chromosomal	O
localization	O
of	O
two	O
KOX	B-DNA
zinc	I-DNA
finger	I-DNA
genes	I-DNA
on	O
chromosome	B-DNA
bands	I-DNA
7q21-q22	B-DNA
.	O


Pulse-field	O
gel	O
electrophoresis	O
(	O
PFGE	O
)	O
analysis	O
showed	O
that	O
these	O
genes	O
are	O
physically	O
located	O
within	O
a	O
DNA	B-DNA
fragment	I-DNA
of	O
250	B-DNA
kb	I-DNA
.	O


From	O
the	O
present	O
and	O
previous	O
data	O
,	O
eighteen	O
different	O
KOX	B-DNA
genes	I-DNA
have	O
been	O
located	O
at	O
least	O
two	O
by	O
two	O
within	O
nine	O
DNA	B-DNA
fragments	I-DNA
of	O
200	O
to	O
580	O
kb	O
.	O


Mononuclear	B-cell_type
leukocytes	I-cell_type
from	O
young	O
or	O
elderly	O
persons	O
were	O
sham-exposed	O
or	O
exposed	O
to	O
influenza	O
virus	O
for	O
1	O
,	O
24	O
,	O
and	O
72	O
h	O
.	O


Immunofluorescent	O
staining	O
and	O
flow	O
cytometric	O
analysis	O
were	O
then	O
used	O
to	O
detect	O
T	B-cell_type
cells	I-cell_type
producing	O
the	O
transcriptional	B-protein
regulating	I-protein
proteins	I-protein
Fos	B-protein
and	O
Jun	B-protein
.	O


Thus	O
,	O
failure	O
of	O
virus-exposed	B-cell_type
T	I-cell_type
cells	I-cell_type
to	O
produce	O
Fos	B-protein
and	O
Jun	B-protein
could	O
contribute	O
to	O
the	O
increase	O
in	O
illness	O
due	O
to	O
influenza	O
virus	O
in	O
the	O
elderly	O
.	O


The	O
regulation	O
of	O
HIV	O
by	O
retinoic	O
acid	O
correlates	O
with	O
cellular	O
expression	O
of	O
the	O
retinoic	B-protein
acid	I-protein
receptors	I-protein
.	O


DESIGN	O
AND	O
METHODS	O
:	O
The	O
effect	O
of	O
all-trans	O
and	O
9-cis	O
RA	O
on	O
HIV-1	O
production	O
in	O
T-lymphoid	B-cell_line
(	O
H9	B-cell_line
,	I-cell_line
CEM	I-cell_line
)	O
and	O
monocytoid	B-cell_line
(	I-cell_line
U937	I-cell_line
,	I-cell_line
THP-1	I-cell_line
)	I-cell_line
cell	I-cell_line
lines	I-cell_line
was	O
measured	O
during	O
acute	O
and	O
chronic	O
infection	O
.	O


The	O
retinoids	O
had	O
weak	O
or	O
no	O
stimulatory	O
effects	O
on	O
HIV	O
production	O
by	O
T-cell	B-cell_line
lines	I-cell_line
.	O


Human	O
RAR	O
alpha	O
expression	O
was	O
unchanged	O
in	O
H9	B-cell_line
and	O
CEM	B-cell_line
cells	I-cell_line
,	O
and	O
elevated	O
in	O
U937	B-cell_line
cells	I-cell_line
,	O
after	O
PMA	O
stimulation	O
.	O


CONCLUSION	O
:	O
The	O
effect	O
of	O
RA	O
on	O
HIV-1	O
expression	O
was	O
cell-type-dependent	O
and	O
partially	O
correlated	O
with	O
cellular	O
expression	O
of	O
RARs	B-protein
.	O


As	O
the	O
protein	B-protein
tyrosine	I-protein
kinase	I-protein
activities	O
p56lck	B-protein
and	O
p59fyn	B-protein
are	O
activated	O
in	O
intact	O
cells	O
by	O
hydrogen	O
peroxide	O
,	O
they	O
are	O
likely	O
targets	O
for	O
GSSG	O
action	O
.	O


The	O
effector	O
phase	O
of	O
cytotoxic	B-cell_type
T	I-cell_type
cell	I-cell_type
responses	O
and	O
IL-2	B-protein
-dependent	O
functions	O
are	O
inhibited	O
even	O
by	O
a	O
partial	O
depletion	O
of	O
the	O
intracellular	O
GSH	O
pool	O
.	O


T	B-cell_type
cells	I-cell_type
from	O
renal	O
cell	O
carcinoma	O
patients	O
exhibit	O
an	O
abnormal	O
pattern	O
of	O
kappa	O
B-specific	O
DNA-binding	O
activity	O
:	O
a	O
preliminary	O
report	O
.	O


The	O
magnitude	O
of	O
kappa	O
B	O
activity	O
in	O
unstimulated	B-cell_type
patient	I-cell_type
T	I-cell_type
cells	I-cell_type
was	O
similar	O
to	O
that	O
observed	O
in	O
T	B-cell_type
cells	I-cell_type
from	O
normal	O
individuals	O
that	O
had	O
been	O
activated	O
in	O
vitro	O
.	O


The	O
second	O
abnormality	O
in	O
kappa	O
B-binding	O
activity	O
in	O
T	B-cell_type
cells	I-cell_type
from	O
these	O
patients	O
is	O
that	O
RelA	B-protein
,	O
a	O
member	O
of	O
the	O
Rel	B-protein
homology	I-protein
family	I-protein
which	O
is	O
part	O
of	O
the	O
normal	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
,	O
was	O
not	O
induced	O
in	O
the	O
nucleus	O
following	O
activation	O
.	O


Hemoglobin	B-protein
switching	O
in	O
humans	O
is	O
accompanied	O
by	O
changes	O
in	O
the	O
ratio	O
of	O
the	O
transcription	B-protein
factors	I-protein
,	O
GATA-1	B-protein
and	O
SP1	B-protein
.	O


We	O
further	O
found	O
that	O
high	O
activities	O
of	O
the	O
transcriptional	B-protein
activators	I-protein
,	O
GATA-1	B-protein
and	O
SP1	B-protein
,	O
are	O
associated	O
with	O
normal	O
adult	O
erythroid	O
differentiation	O
.	O


MATERIALS	O
AND	O
METHODS	O
:	O
In	O
the	O
present	O
work	O
,	O
we	O
have	O
studied	O
,	O
the	O
activities	O
of	O
GATA-1	B-protein
and	O
SP1	B-protein
during	O
differentiation	O
of	O
cultured	O
erythroid	B-cell_type
progenitors	I-cell_type
derived	O
from	O
cord	O
blood	O
and	O
from	O
fetal	O
livers	O
,	O
as	O
well	O
as	O
from	O
beta	O
zero-thalassemia	O
patients	O
.	O


On	O
the	O
other	O
hand	O
,	O
in	O
cultures	O
of	O
2	O
beta	O
zero-thalassemia	O
patients	O
without	O
high	O
HbF	B-protein
,	O
``	O
adult	O
''	O
pattern	O
was	O
observed	O
.	O


Our	O
studies	O
also	O
demonstrate	O
that	O
under	O
anemic	O
stress	O
,	O
recruitment	O
of	O
fetal	B-cell_type
progenitors	I-cell_type
may	O
occur	O
in	O
adulthood	O
.	O


Accompanying	O
the	O
rapid	O
turnover	O
of	O
the	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
protein	I-protein
is	O
simultaneous	O
translocation	O
of	O
NF-kappa	B-protein
B-related	I-protein
transcription	I-protein
factors	I-protein
to	O
nuclei	O
of	O
adhered	O
monocytes	O
.	O


Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
two	O
interactive	O
mechanisms	O
regulate	O
monocytic	B-RNA
I	I-RNA
kappa	I-RNA
B	I-RNA
alpha/MAD-3	I-RNA
mRNA	I-RNA
levels	O
.	O


The	O
intracellular	B-protein
dioxin	I-protein
receptor	I-protein
mediates	O
signal	O
transduction	O
by	O
dioxin	O
and	O
functions	O
as	O
a	O
ligand-activated	B-protein
transcription	I-protein
factor	I-protein
.	O


Deletion	O
of	O
the	O
PAS	B-protein
domain	I-protein
of	O
the	O
receptor	O
resulted	O
in	O
constitutive	O
dimerization	O
with	O
Arnt	B-protein
.	O


It	O
was	O
not	O
possible	O
to	O
reconstitute	O
dioxin	B-protein
receptor	I-protein
function	O
with	O
proteins	O
expressed	O
in	O
wheat	O
germ	O
lysate	O
.	O


Whereas	O
ligand-binding	O
activity	O
correlated	O
with	O
association	O
with	O
hsp90	B-protein
,	O
bHLH-	O
hsp90	B-protein
interaction	O
appeared	O
to	O
be	O
important	O
for	O
DNA-binding	O
activity	O
but	O
not	O
for	O
dimerization	O
of	O
the	O
receptor	O
.	O


Aspirin-like	O
drugs	O
(	O
ALD	O
)	O
induce	O
calcium	O
mobilization	O
,	O
an	O
essential	O
component	O
of	O
T	O
cell	O
activation	O
,	O
but	O
do	O
not	O
induce	O
the	O
biosynthesis	O
of	O
IL-2	B-protein
.	O


The	O
expression	O
of	O
AP-1	B-protein
depended	O
on	O
calcium	O
mobilization	O
and	O
PKC	B-protein
activation	O
.	O


The	O
signaling	O
pathways	O
involving	O
PKC	B-protein
activation	O
,	O
calcium	O
mobilization	O
and	O
ras	B-protein
activation	O
combine	O
to	O
provide	O
the	O
necessary	O
components	O
for	O
production	O
of	O
IL-2	B-protein
during	O
T	O
cell	O
activation	O
.	O


Oct-1	B-protein
and	O
Oct-2	B-protein
are	O
human	O
transcriptional	B-protein
activators	I-protein
that	O
bind	O
to	O
the	O
same	O
DNA	O
element	O
but	O
activate	O
distinct	O
sets	O
of	O
genes	O
.	O


The	O
induction	O
of	O
cell	O
death	O
in	O
lymphoid	B-cell_type
cells	I-cell_type
by	O
glucocorticoids	O
is	O
one	O
of	O
the	O
earliest	O
and	O
most	O
thoroughly	O
studied	O
models	O
of	O
apoptosis	O
.	O


Interleukin-2	B-protein
induces	O
tyrosine	O
phosphorylation	O
and	O
nuclear	O
translocation	O
of	O
stat3	B-protein
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O


An	O
early	O
biochemical	O
event	O
associated	O
with	O
T	O
cell	O
activation	O
through	O
the	O
interleukin-2	B-protein
receptor	I-protein
(	O
IL-2R	B-protein
)	O
is	O
tyrosine	O
phosphorylation	O
of	O
several	O
intracellular	O
substrates	O
.	O


Here	O
,	O
we	O
report	O
that	O
stimulation	O
through	O
the	O
IL-2R	B-protein
induced	O
tyrosine	O
phosphorylation	O
and	O
subsequent	O
nuclear	O
translocation	O
of	O
stat3	B-protein
,	O
a	O
newly	O
identified	O
member	O
of	O
the	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
(	I-protein
STAT	I-protein
)	I-protein
family	I-protein
of	O
proteins	O
.	O


This	O
protein	O
had	O
an	O
apparent	O
molecular	O
mass	O
of	O
84	O
kDa	O
and	O
was	O
not	O
recognized	O
by	O
stat3	B-protein
or	O
stat1	B-protein
mAb	I-protein
or	O
antisera	O
.	O


Tax	O
acts	O
indirectly	O
by	O
inducing	O
or	O
modifying	O
the	O
action	O
of	O
various	O
host	O
transcription	B-protein
factors	I-protein
,	O
including	O
members	O
of	O
the	O
NF-kappa	B-protein
B/Rel	I-protein
family	I-protein
of	O
enhancer-binding	B-protein
proteins	I-protein
.	O


In	O
contrast	O
to	O
prior	O
in	O
vitro	O
studies	O
,	O
at	O
least	O
a	O
fraction	O
of	O
the	O
phosphorylated	O
form	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
remains	O
physically	O
associated	O
with	O
the	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
in	O
vivo	O
but	O
is	O
subject	O
to	O
rapid	O
degradation	O
,	O
thereby	O
promoting	O
the	O
nuclear	O
translocation	O
of	O
the	O
active	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
.	O


Activation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
vivo	O
is	O
regulated	O
by	O
multiple	O
phosphorylations	O
.	O


In	O
HeLa	B-cell_line
cells	I-cell_line
as	O
well	O
as	O
in	O
B	B-cell_type
cells	I-cell_type
,	O
TNF-alpha	O
rapidly	O
induced	O
nuclear	O
translocation	O
primarily	O
of	O
p50-p65	B-protein
,	O
but	O
not	O
of	O
c-rel	B-protein
.	O


Both	O
NF-kappa	B-protein
B	I-protein
precursors	O
and	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
became	O
strongly	O
phosphorylated	O
with	O
the	O
same	O
kinetics	O
.	O


In	O
addition	O
to	O
the	O
inducible	O
phosphorylation	O
after	O
stimulation	O
,	O
B	B-cell_type
lymphocytes	I-cell_type
containing	O
constitutive	O
nuclear	O
NF-kappa	B-protein
B	I-protein
revealed	O
constitutively	O
phosphorylated	O
p65	B-protein
and	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O


As	O
an	O
in	O
vitro	O
model	O
we	O
show	O
that	O
phosphorylation	O
of	O
p105	B-protein
impedes	O
its	O
ability	O
to	O
interact	O
with	O
NF-kappa	B-protein
B	I-protein
,	O
as	O
has	O
been	O
shown	O
before	O
for	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O


Furthermore	O
,	O
we	O
found	O
that	O
the	O
induction	O
by	O
hydrogen	O
peroxide	O
of	O
NF-kappa	B-protein
B	I-protein
translocation	O
to	O
the	O
nucleus	O
,	O
which	O
is	O
assumed	O
to	O
be	O
triggered	O
by	O
reactive	O
oxygen	O
intermediates	O
,	O
also	O
coincided	O
with	O
incorporation	O
of	O
phosphate	O
into	O
the	O
same	O
subunits	O
that	O
were	O
modified	O
after	O
stimulation	O
by	O
TNF-alpha	B-protein
.	O


It	O
is	O
well	O
documented	O
that	O
treatment	O
of	O
serum-grown	B-cell_line
HL60	I-cell_line
cells	I-cell_line
with	O
10	O
(	O
-7	O
)	O
M	O
all-trans	O
retinoic	O
acid	O
(	O
all-trans	O
RA	O
)	O
induces	O
neutrophil	B-cell_type
differentiation	O
,	O
whereas	O
treatment	O
with	O
10	O
(	O
-7	O
)	O
M	O
1	O
alpha	O
,	O
25	O
dihydroxyvitamin	O
D3	O
(	O
D3	O
)	O
induces	O
differentiation	O
towards	O
monocytes	B-cell_type
.	O


Treatment	O
of	O
serum-free	B-cell_line
grown	I-cell_line
HL60	I-cell_line
cells	I-cell_line
with	O
5	O
x	O
10	O
(	O
-7	O
)	O
M	O
all-trans	O
RA	O
or	O
9-cis	O
RA	O
resulted	O
in	O
sub-optimal	O
neutrophil	O
differentiation	O
(	O
up	O
to	O
25	O
%	O
mature	O
cells	O
)	O
.	O


Cross	O
titration	O
analyses	O
of	O
the	O
effects	O
of	O
9-cis	O
RA	O
and	O
D3	O
on	O
HL60	B-cell_line
cell	I-cell_line
differentiation	O
were	O
undertaken	O
to	O
determine	O
the	O
boundaries	O
of	O
the	O
concentrations	O
of	O
each	O
agent	O
,	O
alone	O
and	O
in	O
combination	O
,	O
that	O
give	O
rise	O
to	O
optimal	O
neutrophil	O
and	O
monocyte	O
differentiation	O
of	O
HL60	B-cell_line
cells	I-cell_line
.	O


Two	O
of	O
these	O
DESTs	B-DNA
,	O
GIG10	B-DNA
and	O
GIG18	B-DNA
,	O
are	O
rapidly	O
induced	O
by	O
dexamethasone	O
within	O
2	O
h	O
of	O
treatment	O
.	O


Activation	O
of	O
human	B-cell_type
thymocytes	I-cell_type
after	O
infection	O
by	O
EBV	O
.	O


However	O
,	O
during	O
infection	O
by	O
EBV	O
,	O
ligation	O
of	O
CD2	B-protein
caused	O
thymocytes	B-cell_type
to	O
proliferate	O
in	O
the	O
absence	O
of	O
exogenous	B-protein
cytokines	I-protein
.	O


In	O
addition	O
,	O
components	O
of	O
the	O
viral	O
replicative	O
pathway	O
were	O
expressed	O
during	O
infection	O
of	O
thymocytes	B-cell_type
.	O


A	O
second	O
transcript	O
was	O
identified	O
as	O
encoding	O
the	O
recently	O
characterized	O
RAZ	B-protein
,	O
which	O
also	O
is	O
associated	O
with	O
replicative	O
infection	O
.	O


Before	O
treatment	O
,	O
at	O
regular	O
intervals	O
during	O
the	O
treatment	O
,	O
1	O
week	O
and	O
finally	O
6	O
weeks	O
after	O
termination	O
of	O
treatment	O
,	O
the	O
effects	O
on	O
glucocorticoid	O
receptor	O
(	O
GR	O
)	O
and	O
methallothionein	O
(	O
MTIIa	O
)	O
mRNA	O
expression	O
levels	O
were	O
examined	O
in	O
peripheral	B-cell_type
lymphocytes	I-cell_type
using	O
a	O
solution	O
hybridization	O
assay	O
.	O


Biphasic	O
control	O
of	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
activation	O
by	O
the	O
T	B-protein
cell	I-protein
receptor	I-protein
complex	I-protein
:	O
role	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
.	O


p50.c-rel	B-protein
heterodimers	I-protein
were	O
also	O
detected	O
bound	O
to	O
this	O
sequence	O
at	O
early	O
time	O
points	O
(	O
7-16	O
h	O
;	O
early	O
)	O
,	O
and	O
both	O
remained	O
active	O
at	O
later	O
time	O
points	O
(	O
40	O
h	O
;	O
late	O
)	O
after	O
activation	O
.	O


Activation	O
also	O
induced	O
c-rel	O
and	O
p105/p50	O
mRNA	O
synthesis	O
,	O
but	O
not	O
p65	B-RNA
mRNA	I-RNA
whose	O
expression	O
was	O
constitutive	O
.	O


Interestingly	O
,	O
all	O
those	O
early	O
and	O
late	O
events	O
,	O
but	O
not	O
the	O
immediate	O
ones	O
,	O
were	O
inhibited	O
by	O
a	O
neutralizing	O
anti-tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	I-protein
TNF-alpha	I-protein
)	I-protein
monoclonal	I-protein
antibody	I-protein
.	O


Cyclosporin	O
A	O
impaired	O
not	O
only	O
early	O
and	O
late	O
,	O
but	O
also	O
immediate	O
events	O
;	O
however	O
,	O
addition	O
of	O
TNF-alpha	B-protein
prevented	O
all	O
inhibition	O
.	O


We	O
report	O
here	O
that	O
three	O
copies	O
of	O
the	O
GC-box	B-DNA
can	O
functionally	O
compensate	O
for	O
the	O
GM-kappa	B-DNA
B/GC-box	I-DNA
region	I-DNA
,	O
suggesting	O
that	O
the	O
GC-motif	O
can	O
function	O
independently	O
of	O
the	O
GM-kappa	B-DNA
B	I-DNA
motif	I-DNA
.	O


We	O
show	O
that	O
depletion	O
of	O
Sp1	B-protein
(	O
A1	B-protein
)	O
from	O
nuclear	O
extracts	O
specifically	O
decreases	O
in	O
vitro	O
transcription	O
activity	O
on	O
GM-CSF	B-protein
templates	O
.	O


A	O
novel	O
DNA	B-DNA
sequence	I-DNA
element	I-DNA
termed	O
the	O
J	B-DNA
element	I-DNA
involved	O
in	O
the	O
regulated	O
expression	O
of	O
class	B-DNA
II	I-DNA
major	I-DNA
histocompatibility	I-DNA
complex	I-DNA
genes	I-DNA
was	O
recently	O
described	O
.	O


This	O
protein	O
appears	O
to	O
require	O
both	O
the	O
S	B-DNA
and	I-DNA
J	I-DNA
elements	I-DNA
,	O
which	O
are	O
separated	O
by	O
10	O
bp	O
for	O
optimal	O
binding	O
.	O


Separation	O
of	O
oxidant-initiated	O
and	O
redox-regulated	O
steps	O
in	O
the	O
NF-kappa	B-protein
B	I-protein
signal	O
transduction	O
pathway	O
.	O


Since	O
internal	O
sites	O
of	O
oxidant	O
production	O
have	O
been	O
shown	O
to	O
play	O
a	O
key	O
role	O
in	O
the	O
cytokine	B-protein
-stimulated	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
and	O
since	O
tyrosine	O
kinase	O
and	O
phosphatase	O
activities	O
are	O
known	O
to	O
be	O
altered	O
by	O
oxidants	O
,	O
these	O
findings	O
suggest	O
that	O
intracellular	O
redox	O
status	O
controls	O
NF-kappa	B-protein
B	I-protein
activation	O
by	O
regulating	O
tyrosine	O
phosphorylation	O
event	O
(	O
s	O
)	O
within	O
the	O
common	O
step	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
signal	O
transduction	O
pathway	O
.	O


Alagille	O
syndrome	O
(	O
AGS	O
)	O
is	O
a	O
well-defined	O
genetic	O
entity	O
assigned	O
to	O
the	O
short	B-DNA
arm	I-DNA
of	O
Chromosome	B-DNA
(	I-DNA
Chr	I-DNA
)	I-DNA
20	I-DNA
by	O
a	O
series	O
of	O
observations	O
of	O
AGS	O
patients	O
associated	O
with	O
microdeletions	O
in	O
this	O
region	O
.	O


Furthermore	O
,	O
retinoic	B-protein
acid	I-protein
receptor	I-protein
(	O
RAR	B-protein
)	O
alpha	O
is	O
able	O
to	O
inhibit	O
in	O
vitro	O
the	O
formation	O
of	O
the	O
complex	O
between	O
the	O
nuclear	O
AP-1	B-protein
/OAP	B-protein
and	O
its	O
specific	O
binding	O
site	O
,	O
resulting	O
in	O
the	O
interference	O
with	O
Oct-2	B-protein
-dependent	O
cis-regulatory	O
function	O
of	O
this	O
AP-1	B-protein
element	O
.	O


The	O
status	O
of	O
X	B-DNA
chromosome	I-DNA
inactivation	O
in	O
blood	O
leukocytes	O
from	O
obligate	O
carriers	O
of	O
XCID	O
was	O
determined	O
from	O
the	O
polymorphic	O
,	O
short	O
tandem	O
repeats	O
(	O
CAG	O
)	O
,	O
in	O
the	O
androgen	B-DNA
receptor	I-DNA
gene	I-DNA
,	O
which	O
also	O
contains	O
a	O
methylation-sensitive	B-DNA
HpaII	I-DNA
site	I-DNA
.	O


As	O
in	O
XSCID	O
,	O
X-chromosome	O
inactivation	O
in	O
obligate	O
carriers	O
of	O
XCID	O
was	O
nonrandom	O
in	O
T	B-cell_type
and	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O


Tissue	B-protein
factor	I-protein
(	O
TF	B-protein
)	O
expression	O
by	O
cells	O
of	O
monocyte/macrophage	B-cell_type
lineage	I-cell_type
represents	O
an	O
important	O
mechanism	O
underlying	O
the	O
initiation	O
of	O
fibrin	B-protein
deposition	O
at	O
sites	O
of	O
extravascular	O
inflammation	O
.	O


Northern	O
blot	O
analysis	O
showed	O
that	O
neither	O
of	O
these	O
agents	O
reduced	O
LPS-stimulated	O
TF	B-protein
mRNA	O
accumulation	O
,	O
thereby	O
suggesting	O
a	O
posttranscriptional	O
mechanism	O
for	O
the	O
effect	O
.	O


Immunofluorescence	O
studies	O
of	O
human	B-cell_type
monocytes	I-cell_type
using	O
polyclonal	O
anti-TF	B-protein
antibody	I-protein
showed	O
that	O
N-acetyl-cysteine	O
treatment	O
prevented	O
the	O
characteristic	O
plasmalemmal	O
localization	O
of	O
TF	B-protein
antigen	I-protein
that	O
occurs	O
in	O
response	O
to	O
LPS	O
.	O


When	O
considered	O
together	O
,	O
these	O
data	O
suggest	O
that	O
antioxidants	O
exert	O
their	O
effects	O
by	O
impairing	O
translation	O
and/or	O
by	O
causing	O
degradation	O
of	O
newly	O
translated	B-protein
protein	I-protein
.	O


The	O
posttranscriptional	O
effect	O
of	O
antioxidants	O
on	O
TF	B-protein
expression	O
data	O
suggests	O
a	O
novel	O
mechanism	O
whereby	O
these	O
agents	O
might	O
modulate	O
monocyte	B-cell_type
/macrophage	B-cell_type
activation	O
.	O


We	O
have	O
detected	O
a	O
specific	O
nuclear	B-protein
protein	I-protein
complex	I-protein
that	O
binds	O
to	O
the	O
element	O
and	O
show	O
that	O
NF-kappa	B-protein
B1	I-protein
(	O
p50	B-protein
)	O
is	O
a	O
part	O
of	O
this	O
complex	O
.	O


A	O
similar	O
increase	O
in	O
IL-2R	B-protein
alpha	I-protein
by	O
TG	O
was	O
also	O
observed	O
in	O
human	B-cell_type
peripheral	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O


However	O
,	O
TG	O
and	O
PMA	O
exhibited	O
a	O
synergistic	O
action	O
on	O
IL-2R	B-protein
alpha	I-protein
expression	O
,	O
suggesting	O
that	O
TG	O
and	O
PMA	O
induce	O
IL-2R	B-protein
alpha	I-protein
through	O
distinct	O
pathways	O
.	O


The	O
agent	O
,	O
17	O
beta-estradiol	O
,	O
but	O
not	O
17	O
alpha-estradiol	O
,	O
significantly	O
reduced	O
PMNs	B-cell_type
chemotaxis	O
to	O
FMLP	O
in	O
a	O
dose-dependent	O
manner	O
(	O
control	O
vs	O
estrogen	O
10	O
(	O
-10	O
)	O
-	O
(	O
-6	O
)	O
M	O
,	O
P	O
<	O
0.05	O
)	O
.	O


Pre-incubation	O
with	O
clomiphene	O
or	O
tamoxifen	O
which	O
are	O
estrogen	O
receptor	O
antagonists	O
,	O
eliminated	O
the	O
inhibitory	O
effect	O
of	O
17	O
beta-estradiol	O
on	O
the	O
chemotaxis	O
of	O
PMNs	B-cell_type
,	O
restoring	O
it	O
to	O
the	O
control	O
level	O
.	O


In	O
addition	O
,	O
the	O
level	O
of	O
estradiol	O
in	O
human	B-cell_type
plasma	I-cell_type
,	O
which	O
PMNs	B-cell_type
were	O
drawn	O
,	O
showed	O
a	O
close	O
,	O
inverse	O
correlation	O
with	O
the	O
PMNs	B-cell_type
chemotaxis	O
to	O
FMLP	O
(	O
r	O
=	O
-0.821	O
p	O
<	O
0.001	O
)	O
.	O


Competition	O
and	O
supershift	O
experiments	O
indicate	O
that	O
Mono	B-protein
B	I-protein
contains	O
a	O
member	O
of	O
the	O
polyomavirus	B-protein
enhancer-binding	I-protein
protein	I-protein
2/core-binding	I-protein
factor	I-protein
(	I-protein
PEBP2/CBF	I-protein
)	I-protein
family	I-protein
,	I-protein
which	O
includes	O
the	O
AML1	O
gene	O
product	O
,	O
while	O
Mono	B-protein
A	I-protein
is	O
a	O
distinct	O
complex	O
preferentially	O
expressed	O
in	O
monocytic	B-cell_type
cells	I-cell_type
.	O


These	O
results	O
indicate	O
that	O
the	O
monocyte/B-cell-specific	B-protein
transcription	I-protein
factor	I-protein
PU.1	B-protein
and	O
the	O
Mono	B-protein
A	I-protein
and	I-protein
Mono	I-protein
B	I-protein
protein	I-protein
complexes	I-protein
act	O
in	O
concert	O
to	O
regulate	O
monocyte-specific	O
transcription	O
of	O
the	O
CSF-1	B-protein
receptor	I-protein
.	O


The	O
simultaneous	O
addition	O
of	O
50-500	O
microM	O
PDTC	O
with	O
these	O
agents	O
blocked	O
NF-kappa	B-protein
B	I-protein
activation	O
and	O
completely	O
abrogated	O
both	O
morphologically	O
apoptotic	O
changes	O
and	O
internucleosomal	O
DNA	O
fragmentation	O
for	O
up	O
to	O
6	O
hr	O
.	O


The	O
inhibitory	O
effect	O
of	O
PDTC	O
was	O
also	O
observed	O
in	O
etoposide	O
-and	O
dexamethasone-induced	O
apoptosis	O
in	O
human	B-cell_type
thymocytes	I-cell_type
at	O
a	O
concentration	O
of	O
1-10	O
microM	O
.	O


A	O
family	O
of	O
serine	B-protein
proteases	I-protein
expressed	O
exclusively	O
in	O
myelo-	O
monocytic	B-cell_type
cells	I-cell_type
specifically	O
processes	O
the	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
subunit	I-protein
p65	I-protein
in	O
vitro	O
and	O
may	O
impair	O
human	O
immunodeficiency	O
virus	O
replication	O
in	O
these	O
cells	O
.	O


``	B-cell_line
Plus	I-cell_line
''	I-cell_line
clones	I-cell_line
replicated	O
the	O
virus	O
efficiently	O
,	O
whereas	O
``	B-cell_line
minus	I-cell_line
''	I-cell_line
clones	I-cell_line
did	O
not	O
.	O


We	O
examined	O
these	O
clones	O
for	O
differences	O
in	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	I-protein
activity	O
which	O
might	O
account	O
for	O
the	O
observed	O
phenomenon	O
.	O


However	O
,	O
the	O
p65	B-protein
subunit	I-protein
was	O
COOH-terminally	O
truncated	O
,	O
as	O
shown	O
by	O
immunoprecipitation	O
.	O


We	O
demonstrate	O
in	O
vitro	O
cleavage	O
of	O
p65	B-protein
by	O
purified	O
elastase	B-protein
and	O
cathepsin	B-protein
G	I-protein
.	O


Biochemical	O
studies	O
demonstrate	O
that	O
OBF-1	B-protein
has	O
no	O
intrinsic	O
DNA-binding	O
activity	O
and	O
recognizes	O
the	O
POU	B-protein
domains	I-protein
of	O
Oct-1	B-protein
and	O
Oct-2	B-protein
,	O
but	O
not	O
those	O
of	O
Oct-4	B-protein
and	O
Oct-6	B-protein
.	O


Modulation	O
of	O
transcription	B-protein
factor	I-protein
NF	I-protein
kappa	I-protein
B	I-protein
activity	O
by	O
intracellular	O
glutathione	O
levels	O
and	O
by	O
variations	O
of	O
the	O
extracellular	O
cysteine	O
supply	O
.	O


Conversely	O
,	O
genistein	O
,	O
another	O
tyrosine	O
kinase	O
inhibitor	O
,	O
totally	O
abolished	O
the	O
expression	O
of	O
the	O
second	O
peak	O
of	O
junB	B-RNA
mRNA	I-RNA
whereas	O
it	O
did	O
not	O
affect	O
the	O
expression	O
of	O
the	O
first	O
peak	O
.	O


Enhanced	O
responsiveness	O
to	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
contributes	O
to	O
the	O
unique	O
phenotype	O
of	O
simian	O
immunodeficiency	O
virus	O
variant	O
SIVsmmPBj14	O
.	O


The	O
level	O
of	O
constitutive	O
NF-kappa	B-protein
B	I-protein
in	O
these	O
cells	O
is	O
variable	O
and	O
is	O
frequently	O
found	O
to	O
be	O
lower	O
in	O
the	O
more	O
mature	B-cell_type
macrophages	I-cell_type
.	O


In	O
this	O
report	O
,	O
we	O
studied	O
the	O
role	O
of	O
SCL	O
in	O
the	O
proliferation	O
of	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
burst-forming	I-cell_type
unit-erythroid	I-cell_type
(	O
BFU-E	B-cell_type
)	O
and	O
the	O
effects	O
of	O
Steel	B-protein
factor	I-protein
on	O
SCL	B-protein
expression	O
in	O
proliferating	B-cell_type
erythroid	I-cell_type
cells	I-cell_type
.	O


BFU-E-derived	B-cell_line
colonies	I-cell_line
increase	O
progressively	O
in	O
size	O
,	O
as	O
determined	O
by	O
cell	O
number	O
,	O
from	O
day	O
7	O
to	O
day	O
14	O
of	O
culture	O
,	O
with	O
the	O
greatest	O
increase	O
in	O
colony	O
size	O
(	O
10-fold	O
expansion	O
)	O
occurring	O
between	O
day	O
7	O
and	O
day	O
10	O
.	O


The	O
increase	O
in	O
SCL	B-protein
protein	O
levels	O
in	O
early	O
erythroid	B-cell_type
precursors	I-cell_type
stimulated	O
with	O
Steel	B-protein
factor	I-protein
suggests	O
one	O
mechanism	O
through	O
which	O
Steel	B-protein
factor	I-protein
may	O
enhance	O
normal	O
erythroid	O
proliferation	O
.	O


Our	O
results	O
implicate	O
C/EBP	B-protein
beta	I-protein
as	O
an	O
important	O
regulator	O
of	O
TNF	B-protein
alpha	I-protein
by	O
myelomonocytic	B-cell_type
cells	I-cell_type
.	O


RNAase	B-protein
protection	O
assays	O
demonstrated	O
that	O
the	O
MMP9	B-protein
activity	O
,	O
unique	O
to	O
infected	B-cell_type
cells	I-cell_type
,	O
is	O
due	O
to	O
increased	O
MMP9	B-protein
mRNA	O
levels	O
.	O


Growth	O
arrest	O
is	O
reversible	O
for	O
G1/G0	B-cell_type
cells	I-cell_type
as	O
indicated	O
by	O
the	O
sequential	O
accumulation	O
and	O
modification	O
of	O
cell	B-protein
cycle	I-protein
regulating	I-protein
proteins	I-protein
.	O


RJ	B-cell_line
2.2.5	I-cell_line
is	O
a	O
human	B-cell_line
B	I-cell_line
cell	I-cell_line
mutant	I-cell_line
derived	O
from	O
the	O
Burkitt	B-cell_line
lymphoma	I-cell_line
Raji	I-cell_line
cell	I-cell_line
which	O
is	O
defective	O
in	O
the	O
AIR-1	O
locus	O
function	O
.	O


Correlation	O
of	O
differentiation-inducing	O
activity	O
of	O
retinoids	O
on	O
human	B-cell_line
leukemia	I-cell_line
cell	I-cell_line
lines	I-cell_line
HL-60	B-cell_line
and	O
NB4	B-cell_line
.	O


A	O
good	O
linear	O
correlation	O
,	O
with	O
an	O
r	O
value	O
of	O
0.91	O
,	O
between	O
the	O
ED50	O
values	O
for	O
the	O
differentiation-inducing	O
activity	O
towards	O
HL-60	B-cell_line
cells	I-cell_line
and	O
that	O
towards	O
NB4	B-cell_line
cells	I-cell_line
was	O
found	O
.	O


J	B-cell_line
delta	I-cell_line
K	I-cell_line
cells	I-cell_line
exhibited	O
very	O
low	O
levels	O
of	O
constitutive	O
HIV	O
production	O
.	O


In	O
vivo	O
occupancy	O
of	O
this	O
site	O
is	O
observed	O
only	O
in	O
the	O
H9	B-cell_line
T-cell	I-cell_line
line	I-cell_line
.	O


Antigenic	O
specificities	O
of	O
human	B-cell_line
CD4+	I-cell_line
T-cell	I-cell_line
clones	I-cell_line
recovered	O
from	O
recurrent	O
genital	O
herpes	O
simplex	O
virus	O
type	O
2	O
lesions	O
.	O


Each	O
of	O
the	O
remaining	O
four	O
patients	O
also	O
yielded	O
at	O
least	O
one	O
type-specific	B-cell_line
T-cell	I-cell_line
clone	I-cell_line
reactive	O
with	O
an	O
HSV-2	O
epitope	O
mapping	O
to	O
approximately	O
0.67	O
to	O
0.73	O
map	O
units	O
.	O


Similarly	O
,	O
Jurkat	B-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
deficient	O
in	O
CD3	O
or	O
CD45	O
expression	O
also	O
gave	O
impaired	O
UV	O
responses	O
.	O


We	O
have	O
investigated	O
the	O
effect	O
of	O
redox	O
changes	O
in	O
vivo	O
on	O
the	O
differentiation	O
of	O
two	O
human	B-cell_line
myeloid	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
HL-60	B-cell_line
and	O
KG-1	B-cell_line
.	O


When	O
cells	O
were	O
preincubated	O
with	O
dihydrolipoic	O
acid	O
(	O
0.2	O
mM	O
)	O
the	O
expression	O
of	O
c-fos	B-RNA
mRNA	I-RNA
was	O
suppressed	O
at	O
30	O
min	O
after	O
stimulation	O
of	O
TPA	O
(	O
0.5	O
microM	O
)	O
whereas	O
in	O
the	O
case	O
of	O
preincubation	O
of	O
alpha-lipoic	O
acid	O
(	O
0.2	O
microM	O
)	O
,	O
the	O
expression	O
was	O
enhanced	O
at	O
30	O
min	O
.	O


These	O
events	O
are	O
accompanied	O
by	O
marked	O
increases	O
in	O
the	O
expression	O
of	O
RAG-1	B-RNA
and	I-RNA
RAG-2	I-RNA
RNAs	I-RNA
.	O


